{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:41:47Z","timestamp":1793922107896,"version":"4.8.0"},"reference-count":1262,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Microbiol Rev"],"published-print":{"date-parts":[[2020,6,17]]},"abstract":"<jats:p>The past 2 decades have seen a revolution in our approach to therapeutic immunosuppression. We have moved from relying on broadly active traditional medications, such as prednisolone or methotrexate, toward more specific agents that often target a single receptor, cytokine, or cell type, using monoclonal antibodies, fusion proteins, or targeted small molecules. This change has transformed the treatment of many conditions, including rheumatoid arthritis, cancers, asthma, and inflammatory bowel disease, but along with the benefits have come risks.<\/jats:p>","DOI":"10.1128\/cmr.00035-19","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T09:19:55Z","timestamp":1591694395000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":172,"title":["Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies"],"prefix":"10.1128","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9864-5699","authenticated-orcid":false,"given":"Joshua S.","family":"Davis","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases and Immunology, John Hunter Hospital, Newcastle, NSW, Australia"},{"name":"Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia"},{"name":"School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ferreira","sequence":"additional","affiliation":[{"name":"School of Medicine, University of New South Wales, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Paige","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Alfred Hospital, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Gedye","sequence":"additional","affiliation":[{"name":"School of Medicine, University of New South Wales, Sydney, NSW, Australia"},{"name":"Department of Oncology, Calvary Mater Hospital, Newcastle, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Boyle","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Immunology, John Hunter Hospital, Newcastle, NSW, Australia"},{"name":"School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.4161\/19420862.2015.989042"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.2174\/1574884712666170809124728"},{"key":"e_1_3_2_4_2","volume-title":"Medicines in development for biologics 2013 report","author":"PhRMA","year":"2013","unstructured":"PhRMA. 2013. Medicines in development for biologics 2013 report. Pharmaceutical Research and Manufacturers of America, Washington, DC."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.2174\/157339711794474620"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.103564"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00040-08"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-7306(08)60153-2"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00302"},{"key":"e_1_3_2_10_2","first-page":"244","article-title":"International classification of various types of monoclonal antibodies","volume":"64","author":"Scheen AJ","year":"2009","unstructured":"Scheen AJ. 2009. International classification of various types of monoclonal antibodies. Rev Med Liege 64:244\u2013247.","journal-title":"Rev Med Liege"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.2.3.11641"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000192105.24583.83"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0285-9"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.03.009"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/0192623311428481"},{"key":"e_1_3_2_16_2","first-page":"107","article-title":"Immune disorders and susceptibility to neoplasms","volume":"4","author":"Prakash O","year":"2002","unstructured":"Prakash O, Gill J, Farr G. 2002. Immune disorders and susceptibility to neoplasms. Ochsner J 4:107\u2013111.","journal-title":"Ochsner J"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.9.4.532"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115453"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/stem.5530130303"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/09629359890910"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0192-0561(99)00005-3"},{"key":"e_1_3_2_22_2","first-page":"387","article-title":"The risk of hospitalized infection in patients with rheumatoid arthritis","volume":"35","author":"Smitten AL","year":"2008","unstructured":"Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, Chan KA. 2008. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 35:387\u2013393.","journal-title":"J Rheumatol"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2016.09.005"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.3.5.16553"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S28801"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2010.03.025"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2007.09.002"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04904-7"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200309000-00002"},{"key":"e_1_3_2_30_2","first-page":"1473","article-title":"Immune status and risk for infection in patients receiving chronic immunosuppressive therapy","volume":"32","author":"Gl\u00fcck T","year":"2005","unstructured":"Gl\u00fcck T, Kiefmann B, Grohmann M, Falk W, Straub RH, Sch\u00f6lmerich J. 2005. Immune status and risk for infection in patients receiving chronic immunosuppressive therapy. J Rheumatol 32:1473\u20131480.","journal-title":"J Rheumatol"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.01.012"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028018754896"},{"key":"e_1_3_2_33_2","first-page":"S173","article-title":"TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy","volume":"11","author":"Maini RN","year":"1993","unstructured":"Maini RN, Brennan FM, Williams R, Chu CQ, Cope AP, Gibbons D, Elliott M, Feldmann M. 1993. TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy. Clin Exp Rheumatol 11(Suppl 8):S173\u2013S175.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.19.1.163"},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"6276","DOI":"10.4049\/jimmunol.159.12.6276","article-title":"A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn\u2019s disease","volume":"159","author":"Plevy SE","year":"1997","unstructured":"Plevy SE, Landers CJ, Prehn J, Carramanzana NM, Deem RL, Shealy D, Targan SR. 1997. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn\u2019s disease. J Immunol 159:6276.","journal-title":"J Immunol"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.2287"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevEukarGeneExpr.v20.i2.10"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.9.4620"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0103008"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2015.01"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1523-2"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071643"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.74.3.1846-1856.2006"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/0192-0561(91)90047-B"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800000222"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90134-C"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(95)90001-2"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.5625\/lar.2015.31.2.78"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.66.2.839-842.1998"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365540410026068"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.8.3725"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.57.7.2115-2122.1989"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.66.12.5999-6003.1998"},{"key":"e_1_3_2_54_2","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.4049\/jimmunol.157.10.4529","article-title":"Afferent phase production of TNF-alpha is required for the development of protective T cell immunity to Cryptococcus neoformans","volume":"157","author":"Huffnagle GB","year":"1996","unstructured":"Huffnagle GB, Toews GB, Burdick MD, Boyd MB, McAllister KS, McDonald RA, Kunkel SL, Strieter RM. 1996. Afferent phase production of TNF-alpha is required for the development of protective T cell immunity to Cryptococcus neoformans. J Immunol 157:4529\u20134536.","journal-title":"J Immunol"},{"key":"e_1_3_2_55_2","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.4049\/jimmunol.160.12.6072","article-title":"Blockade of endogenous TNF-alpha exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms","volume":"160","author":"Allendoerfer R","year":"1998","unstructured":"Allendoerfer R, Deepe GS, Jr. 1998. Blockade of endogenous TNF-alpha exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms. J Immunol 160:6072\u20136082.","journal-title":"J Immunol"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030275"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-014-3006-2"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-018-0283-4"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1043-6618(02)00264-5"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.2174\/138945010790309939"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.73"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13691"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1221398"},{"key":"e_1_3_2_64_2","unstructured":". 2012. Enbrel (etanercept). Full prescribing information. Reference ID 3225283. Food and Drug Administration Silver Spring MD."},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2017.1366006"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-015-0542-z"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.09.056"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22961"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1159\/000343605"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2013.834961"},{"key":"e_1_3_2_71_2","unstructured":". 2017. Cimzia (certolizumab pegol). Full prescribing information. Reference ID 4036048. Food and Drug Administration Silver Spring MD. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125160s270lbl.pdf."},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.reumae.2015.01.005"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2017.1285857"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.123"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2014.970165"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1517\/14622416.5.5.479"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2017.26"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.101009"},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008794.pub2"},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1009036"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201338"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2014.55.2.442"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.137422"},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.081246"},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12154"},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2011.01434.x"},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3182380a76"},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/ldp036"},{"key":"e_1_3_2_89_2","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2015.1011616"},{"key":"e_1_3_2_90_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i44.7867"},{"key":"e_1_3_2_91_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker190"},{"key":"e_1_3_2_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.11.025"},{"key":"e_1_3_2_93_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.081513"},{"key":"e_1_3_2_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.11.043"},{"key":"e_1_3_2_95_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.101386"},{"key":"e_1_3_2_96_2","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e32831de271"},{"key":"e_1_3_2_97_2","doi-asserted-by":"publisher","DOI":"10.1086\/605498"},{"key":"e_1_3_2_98_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.146"},{"key":"e_1_3_2_99_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23112"},{"key":"e_1_3_2_100_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20217"},{"key":"e_1_3_2_101_2","doi-asserted-by":"publisher","DOI":"10.2174\/1874312900903010030"},{"key":"e_1_3_2_102_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2010.04.014"},{"key":"e_1_3_2_103_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2009.279"},{"key":"e_1_3_2_104_2","doi-asserted-by":"publisher","DOI":"10.2174\/187152809787582543"},{"key":"e_1_3_2_105_2","doi-asserted-by":"publisher","DOI":"10.1006\/clim.2000.4835"},{"key":"e_1_3_2_106_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.67.7.3571-3579.1999"},{"key":"e_1_3_2_107_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.3.1847-1855.2001"},{"key":"e_1_3_2_108_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12644"},{"key":"e_1_3_2_109_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11137"},{"key":"e_1_3_2_110_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012567"},{"key":"e_1_3_2_111_2","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12576"},{"key":"e_1_3_2_112_2","doi-asserted-by":"publisher","DOI":"10.4065\/83.2.181"},{"key":"e_1_3_2_113_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0267"},{"key":"e_1_3_2_114_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10583"},{"key":"e_1_3_2_115_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000180044.19285.9a"},{"key":"e_1_3_2_116_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14416"},{"key":"e_1_3_2_117_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14146"},{"key":"e_1_3_2_118_2","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.21193"},{"key":"e_1_3_2_119_2","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/410521"},{"key":"e_1_3_2_120_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1292885"},{"key":"e_1_3_2_121_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2010.02238.x"},{"key":"e_1_3_2_122_2","doi-asserted-by":"publisher","DOI":"10.1097\/meg.0b013e3283329d13"},{"key":"e_1_3_2_123_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i36.10274"},{"key":"e_1_3_2_124_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21519"},{"key":"e_1_3_2_125_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.066761"},{"key":"e_1_3_2_126_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204769"},{"key":"e_1_3_2_127_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14420"},{"key":"e_1_3_2_128_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.221127"},{"key":"e_1_3_2_129_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.01.012"},{"key":"e_1_3_2_130_2","doi-asserted-by":"publisher","DOI":"10.4081\/reumatismo.2010.283"},{"key":"e_1_3_2_131_2","doi-asserted-by":"publisher","DOI":"10.1080\/03009740701716876"},{"key":"e_1_3_2_132_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204978"},{"key":"e_1_3_2_133_2","doi-asserted-by":"publisher","DOI":"10.1159\/000370238"},{"key":"e_1_3_2_134_2","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-220184"},{"key":"e_1_3_2_135_2","first-page":"914","article-title":"Mycobacterium fortuitum infection following adalimumab treatment for psoriasis and subsequent complication-free treatment with alternate TNF-a blockers","volume":"10","author":"Chang MB","year":"2011","unstructured":"Chang MB, Sri JC, Driscoll M, Gaspari AA. 2011. Mycobacterium fortuitum infection following adalimumab treatment for psoriasis and subsequent complication-free treatment with alternate TNF-a blockers. J Drugs Dermatol 10:914\u2013916.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_2_136_2","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2017.1250606"},{"key":"e_1_3_2_137_2","doi-asserted-by":"publisher","DOI":"10.2217\/imt.13.10"},{"key":"e_1_3_2_138_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04037.x"},{"key":"e_1_3_2_139_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.9.829"},{"key":"e_1_3_2_140_2","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/367131"},{"key":"e_1_3_2_141_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20702"},{"key":"e_1_3_2_142_2","first-page":"107","article-title":"Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C","volume":"31","author":"Oniankitan O","year":"2004","unstructured":"Oniankitan O, Duvoux C, Challine D, Mallat A, Chevalier X, Pawlotsky JM, Claudepierre P. 2004. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 31:107\u2013109.","journal-title":"J Rheumatol"},{"key":"e_1_3_2_143_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200102000-00016"},{"key":"e_1_3_2_144_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-006-0394-z"},{"key":"e_1_3_2_145_2","first-page":"1944","article-title":"Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection","volume":"35","author":"Ferri C","year":"2008","unstructured":"Ferri C, Ferraccioli G, Ferrari D, Galeazzi M, Lapadula G, Montecucco C, Triolo G, Valentini G, Valesini G. 2008. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol 35:1944\u20131949.","journal-title":"J Rheumatol"},{"key":"e_1_3_2_146_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2009.06.002"},{"key":"e_1_3_2_147_2","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e31824e9151"},{"key":"e_1_3_2_148_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2006.05.012"},{"key":"e_1_3_2_149_2","first-page":"407","article-title":"Infliximab in the treatment of an HIV positive patient with Reiter\u2019s syndrome","volume":"30","author":"Gaylis N","year":"2003","unstructured":"Gaylis N. 2003. Infliximab in the treatment of an HIV positive patient with Reiter\u2019s syndrome. J Rheumatol 30:407\u2013411.","journal-title":"J Rheumatol"},{"key":"e_1_3_2_150_2","first-page":"38","article-title":"Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies","volume":"101","author":"Nakamura M","year":"2018","unstructured":"Nakamura M, Abrouk M, Farahnik B, Zhu TH, Bhutani T. 2018. Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies. Cutis 101:38.","journal-title":"Cutis"},{"key":"e_1_3_2_151_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-008-0628-x"},{"key":"e_1_3_2_152_2","doi-asserted-by":"publisher","DOI":"10.2147\/btt.2009.3099"},{"key":"e_1_3_2_153_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21734"},{"key":"e_1_3_2_154_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)05246-0"},{"key":"e_1_3_2_155_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20568"},{"key":"e_1_3_2_156_2","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2016.3548"},{"key":"e_1_3_2_157_2","doi-asserted-by":"publisher","DOI":"10.1086\/383317"},{"key":"e_1_3_2_158_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"e_1_3_2_159_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030815"},{"key":"e_1_3_2_160_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050516"},{"key":"e_1_3_2_161_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10758"},{"key":"e_1_3_2_162_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ299"},{"key":"e_1_3_2_163_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24283"},{"key":"e_1_3_2_164_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20866"},{"key":"e_1_3_2_165_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-012-2405-z"},{"key":"e_1_3_2_166_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-007-0660-8"},{"key":"e_1_3_2_167_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.006809-0"},{"key":"e_1_3_2_168_2","first-page":"2432","article-title":"Primary cutaneous Nocardia otitidiscaviarum infection in a patient with rheumatoid arthritis treated with infliximab","volume":"32","author":"Fabre S","year":"2005","unstructured":"Fabre S, Gibert C, Lechiche C, Jorgensen C, Sany J. 2005. Primary cutaneous Nocardia otitidiscaviarum infection in a patient with rheumatoid arthritis treated with infliximab. J Rheumatol 32:2432.","journal-title":"J Rheumatol"},{"key":"e_1_3_2_169_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04206.x"},{"key":"e_1_3_2_170_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-002-0925-9"},{"key":"e_1_3_2_171_2","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.96"},{"key":"e_1_3_2_172_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100012105"},{"key":"e_1_3_2_173_2","doi-asserted-by":"publisher","DOI":"10.1080\/24725625.2017.1295504"},{"key":"e_1_3_2_174_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2005.02642.x"},{"key":"e_1_3_2_175_2","doi-asserted-by":"publisher","DOI":"10.4065\/75.10.1093"},{"key":"e_1_3_2_176_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10308"},{"key":"e_1_3_2_177_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15640-7"},{"key":"e_1_3_2_178_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.043299"},{"key":"e_1_3_2_179_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-015-9914-1"},{"key":"e_1_3_2_180_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit489"},{"key":"e_1_3_2_181_2","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-012-0615-z"},{"key":"e_1_3_2_182_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24095"},{"key":"e_1_3_2_183_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.01.023"},{"key":"e_1_3_2_184_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0213-005x(06)73780-6"},{"key":"e_1_3_2_185_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2013.11.014"},{"key":"e_1_3_2_186_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22470"},{"key":"e_1_3_2_187_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-014032"},{"key":"e_1_3_2_188_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23383"},{"key":"e_1_3_2_189_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60506-7"},{"key":"e_1_3_2_190_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24638"},{"key":"e_1_3_2_191_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.099010"},{"key":"e_1_3_2_192_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21788"},{"key":"e_1_3_2_193_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204195"},{"key":"e_1_3_2_194_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.04.039"},{"key":"e_1_3_2_195_2","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2016.24"},{"key":"e_1_3_2_196_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw064"},{"key":"e_1_3_2_197_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2017.12.008"},{"key":"e_1_3_2_198_2","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcw197"},{"key":"e_1_3_2_199_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10354-016-0527-1"},{"key":"e_1_3_2_200_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-013-1873-1"},{"key":"e_1_3_2_201_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0336-2"},{"key":"e_1_3_2_202_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203660"},{"key":"e_1_3_2_203_2","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X11413315"},{"key":"e_1_3_2_204_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067594"},{"key":"e_1_3_2_205_2","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2014-000044"},{"key":"e_1_3_2_206_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-11-145"},{"key":"e_1_3_2_207_2","first-page":"C4480","article-title":"Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment","volume":"59","author":"Nordgaard-Lassen I","year":"2012","unstructured":"Nordgaard-Lassen I, Dahlerup JF, Belard E, Gerstoft J, Kjeldsen J, Kragballe K, Ravn P, Sorensen IJ, Theede K, Tjellesen L Danish Society for Gastroenterology,. 2012. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment. Dan Med J 59:C4480.","journal-title":"Dan Med J"},{"key":"e_1_3_2_208_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12598"},{"key":"e_1_3_2_209_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.12.013"},{"key":"e_1_3_2_210_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2005.046797"},{"key":"e_1_3_2_211_2","first-page":"560","article-title":"Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis","volume":"159","author":"Salpeter SR","year":"1993","unstructured":"Salpeter SR. 1993. Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis. West J Med 159:560\u2013564.","journal-title":"West J Med"},{"key":"e_1_3_2_212_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200512-1953OC"},{"key":"e_1_3_2_213_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104875"},{"key":"e_1_3_2_214_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714283"},{"key":"e_1_3_2_215_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21513"},{"key":"e_1_3_2_216_2","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2009.025"},{"key":"e_1_3_2_217_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04570.x"},{"key":"e_1_3_2_218_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh167"},{"key":"e_1_3_2_219_2","first-page":"816","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","unstructured":"Centers for Disease Control and Prevention. 2012. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 61:816\u2013819.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_2_220_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.79"},{"key":"e_1_3_2_221_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-014-0431-x"},{"key":"e_1_3_2_222_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-1-200901060-00008"},{"key":"e_1_3_2_223_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.10031014"},{"key":"e_1_3_2_224_2","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/641757"},{"key":"e_1_3_2_225_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri3839"},{"key":"e_1_3_2_226_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M302709200"},{"key":"e_1_3_2_227_2","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2011.153"},{"key":"e_1_3_2_228_2","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevImmunol.2014010373"},{"key":"e_1_3_2_229_2","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.42"},{"key":"e_1_3_2_230_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902761"},{"key":"e_1_3_2_231_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02844-06"},{"key":"e_1_3_2_232_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002464"},{"key":"e_1_3_2_233_2","first-page":"73","article-title":"The role of T-cell subsets in Mycobacterium tuberculosis infection","volume":"5","author":"Boom WH","year":"1996","unstructured":"Boom WH. 1996. The role of T-cell subsets in Mycobacterium tuberculosis infection. Infect Agents Dis 5:73\u201381.","journal-title":"Infect Agents Dis"},{"key":"e_1_3_2_234_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400019"},{"key":"e_1_3_2_235_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00097-13"},{"key":"e_1_3_2_236_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-015-0490-8"},{"key":"e_1_3_2_237_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.282.5386.121"},{"key":"e_1_3_2_238_2","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200012)30:12<3689::AID-IMMU3689>3.0.CO;2-4"},{"key":"e_1_3_2_239_2","unstructured":". 2003. Package insert: Simulect (basiliximab) Novartis Pharmaceuticals Company. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2003\/basnov010203LB.htm. Accessed 7 July 2019."},{"key":"e_1_3_2_240_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2015.08.009"},{"key":"e_1_3_2_241_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05631.x"},{"key":"e_1_3_2_242_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13182"},{"key":"e_1_3_2_243_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2008.12.028"},{"key":"e_1_3_2_244_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2007.12.001"},{"key":"e_1_3_2_245_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.41031"},{"key":"e_1_3_2_246_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.080002"},{"key":"e_1_3_2_247_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum1022"},{"key":"e_1_3_2_248_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.091066"},{"key":"e_1_3_2_249_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.145946"},{"key":"e_1_3_2_250_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204653"},{"key":"e_1_3_2_251_2","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2014.935329"},{"key":"e_1_3_2_252_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204164"},{"key":"e_1_3_2_253_2","unstructured":". 2011. Full prescribing information: Adcetris (brentuximab vedotin). Reference ID 3662552. Food and Drug Administration Silver Spring MD."},{"key":"e_1_3_2_254_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.05.026"},{"key":"e_1_3_2_255_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402"},{"key":"e_1_3_2_256_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1198775"},{"key":"e_1_3_2_257_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx091"},{"key":"e_1_3_2_258_2","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2017.1366854"},{"key":"e_1_3_2_259_2","unstructured":"Brooks M. 2 March 2018. MS drug daclizumab (Zinbryta) pulled from the market. Medscape New York NY. https:\/\/www.medscape.com\/viewarticle\/893352. Accessed 10 November 2019."},{"key":"e_1_3_2_260_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200107263450403"},{"key":"e_1_3_2_261_2","unstructured":". 2011. Amevive (alefacept) voluntarily discontinued in the U.S. National Psoriasis Foundation Portland OR. https:\/\/www.psoriasis.org\/media\/press-releases\/amevive-alefacept-voluntarily-discontinued-us. Accessed 10 November 2019."},{"key":"e_1_3_2_262_2","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.19931"},{"key":"e_1_3_2_263_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7393.789"},{"key":"e_1_3_2_264_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000109643.32659.C4"},{"key":"e_1_3_2_265_2","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200317040-00006"},{"key":"e_1_3_2_266_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2010.02.088"},{"key":"e_1_3_2_267_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200110150-00014"},{"key":"e_1_3_2_268_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)09278-7"},{"key":"e_1_3_2_269_2","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12621"},{"key":"e_1_3_2_270_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2010.09.169"},{"key":"e_1_3_2_271_2","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2002.30302"},{"key":"e_1_3_2_272_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2004.09.010"},{"key":"e_1_3_2_273_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2006.09.002"},{"key":"e_1_3_2_274_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002790"},{"key":"e_1_3_2_275_2","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13190"},{"key":"e_1_3_2_276_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2005.09.192"},{"key":"e_1_3_2_277_2","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000687"},{"key":"e_1_3_2_278_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13739"},{"key":"e_1_3_2_279_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2015.03.011"},{"key":"e_1_3_2_280_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0112"},{"key":"e_1_3_2_281_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050524"},{"key":"e_1_3_2_282_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22070"},{"key":"e_1_3_2_283_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.055111"},{"key":"e_1_3_2_284_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2010.10.011"},{"key":"e_1_3_2_285_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2019.01.009"},{"key":"e_1_3_2_286_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket221"},{"key":"e_1_3_2_287_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.10.011"},{"key":"e_1_3_2_288_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-016-0060-2"},{"key":"e_1_3_2_289_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22786"},{"key":"e_1_3_2_290_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21654"},{"key":"e_1_3_2_291_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22750"},{"key":"e_1_3_2_292_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140103"},{"key":"e_1_3_2_293_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0178035"},{"key":"e_1_3_2_294_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.1280-18"},{"key":"e_1_3_2_295_2","first-page":"28","article-title":"Epstein-Barr virus associated hemophagocytic lymphohistiocytosis in a rheumatic patient receiving abatacept therapy","volume":"97","author":"Dalal RS","year":"2014","unstructured":"Dalal RS, LeGolvan MP, Stachurski DR, Goldberg LR. 2014. Epstein-Barr virus associated hemophagocytic lymphohistiocytosis in a rheumatic patient receiving abatacept therapy. R I Med J (2013) 97:28\u201331.","journal-title":"R I Med J (2013)"},{"key":"e_1_3_2_296_2","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2013-009731"},{"key":"e_1_3_2_297_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0171623"},{"key":"e_1_3_2_298_2","doi-asserted-by":"publisher","DOI":"10.1086\/597089"},{"key":"e_1_3_2_299_2","doi-asserted-by":"publisher","DOI":"10.1038\/205143a0"},{"key":"e_1_3_2_300_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-078071"},{"key":"e_1_3_2_301_2","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.AID-0019-2014"},{"key":"e_1_3_2_302_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00005-008-0014-5"},{"key":"e_1_3_2_303_2","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/13.12.1583"},{"key":"e_1_3_2_304_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0709205105"},{"key":"e_1_3_2_305_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401849"},{"key":"e_1_3_2_306_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302848"},{"key":"e_1_3_2_307_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302661"},{"key":"e_1_3_2_308_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.69.2.1339-1343.1995"},{"key":"e_1_3_2_309_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.15.6901"},{"key":"e_1_3_2_310_2","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12094"},{"key":"e_1_3_2_311_2","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2015.25"},{"key":"e_1_3_2_312_2","first-page":"295","article-title":"Characteristics of regulatory B cells in patients with chronic hepatitis B virus infection in different immune phases","volume":"23","author":"Wang G","year":"2017","unstructured":"Wang G, Liu Y, Huang R, Jia B, Su R, Sun Z, Tian C, Xiong Y, Xia J, Yan X, Zhang Z, Wu C. 2017. Characteristics of regulatory B cells in patients with chronic hepatitis B virus infection in different immune phases. Discov Med 23:295\u2013304.","journal-title":"Discov Med"},{"key":"e_1_3_2_313_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000879"},{"key":"e_1_3_2_314_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.80.8.3923-3934.2006"},{"key":"e_1_3_2_315_2","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2015.364"},{"key":"e_1_3_2_316_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.10.6023-6034.2005"},{"key":"e_1_3_2_317_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0607026104"},{"key":"e_1_3_2_318_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.02.080"},{"key":"e_1_3_2_319_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01708-08"},{"key":"e_1_3_2_320_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2014.08.007"},{"key":"e_1_3_2_321_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0630530100"},{"key":"e_1_3_2_322_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00198-11"},{"key":"e_1_3_2_323_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01762-08"},{"key":"e_1_3_2_324_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000106"},{"key":"e_1_3_2_325_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00110-09"},{"key":"e_1_3_2_326_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3565"},{"key":"e_1_3_2_327_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002739"},{"key":"e_1_3_2_328_2","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.4049\/jimmunol.157.5.2168","article-title":"HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression","volume":"157","author":"Baum LL","year":"1996","unstructured":"Baum LL, Cassutt KJ, Knigge K, Khattri R, Margolick J, Rinaldo C, Kleeberger CA, Nishanian P, Henrard DR, Phair J. 1996. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol 157:2168.","journal-title":"J Immunol"},{"key":"e_1_3_2_329_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.07.043"},{"key":"e_1_3_2_330_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2233"},{"key":"e_1_3_2_331_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000229482.27398.ad"},{"key":"e_1_3_2_332_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.71.8.4225-4228.2003"},{"key":"e_1_3_2_333_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2014.10.005"},{"key":"e_1_3_2_334_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200839148"},{"key":"e_1_3_2_335_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(06)91001-3"},{"key":"e_1_3_2_336_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.73.10.6350-6362.2005"},{"key":"e_1_3_2_337_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01840-06"},{"key":"e_1_3_2_338_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.71.9.5273-5279.2003"},{"key":"e_1_3_2_339_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.51.2.556-562.1986"},{"key":"e_1_3_2_340_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.70.5.2598-2604.2002"},{"key":"e_1_3_2_341_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.58.6.1914-1918.1990"},{"key":"e_1_3_2_342_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00892-10"},{"key":"e_1_3_2_343_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.73.2.1141-1150.2005"},{"key":"e_1_3_2_344_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901638"},{"key":"e_1_3_2_345_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2010.11.005"},{"key":"e_1_3_2_346_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003662"},{"key":"e_1_3_2_347_2","doi-asserted-by":"publisher","DOI":"10.1038\/32190"},{"key":"e_1_3_2_348_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4419-9533-9_12"},{"key":"e_1_3_2_349_2","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12543620"},{"key":"e_1_3_2_350_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.23.14733"},{"key":"e_1_3_2_351_2","first-page":"17","article-title":"CD20: a gene in search of a function","volume":"27","author":"Riley JK","year":"2000","unstructured":"Riley JK, Sliwkowski MX. 2000. CD20: a gene in search of a function. Semin Oncol 27:17\u201324.","journal-title":"Semin Oncol"},{"key":"e_1_3_2_352_2","unstructured":". 2010. Rituxan (rituximab). Full prescribing information. Food and Drug Administration Silver Spring MD. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/103705s5311lbl.pdf."},{"key":"e_1_3_2_353_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-15-178"},{"key":"e_1_3_2_354_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.24.021605.090517"},{"key":"e_1_3_2_355_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-563627"},{"key":"e_1_3_2_356_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000593"},{"key":"e_1_3_2_357_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0251"},{"key":"e_1_3_2_358_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.128"},{"key":"e_1_3_2_359_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70300-X"},{"key":"e_1_3_2_360_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-503862"},{"key":"e_1_3_2_361_2","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9084759"},{"key":"e_1_3_2_362_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458519872889:1352458519872889"},{"key":"e_1_3_2_363_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-341131"},{"key":"e_1_3_2_364_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-551580"},{"key":"e_1_3_2_365_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01486.x"},{"key":"e_1_3_2_366_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25597"},{"key":"e_1_3_2_367_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.1637"},{"key":"e_1_3_2_368_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar1954"},{"key":"e_1_3_2_369_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016040449"},{"key":"e_1_3_2_370_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.11.014"},{"key":"e_1_3_2_371_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.05.011"},{"key":"e_1_3_2_372_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23059"},{"key":"e_1_3_2_373_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24722"},{"key":"e_1_3_2_374_2","unstructured":". 2009. Arzerra (ofatumumab). Full prescribing information. Reference ID 3490691. Food and Drug Administration Silver Spring MD."},{"key":"e_1_3_2_375_2","unstructured":". 2017. Ocrevus (ocrelizumab). Full prescribing information. Reference ID 4076448. Food and Drug Administration Silver Spring MD."},{"key":"e_1_3_2_376_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087379"},{"key":"e_1_3_2_377_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.38037"},{"key":"e_1_3_2_378_2","unstructured":". 2013. Gazyva (obinutuzumab). Full prescribing information. Reference ID 3893320. Food and Drug Administration Silver Spring MD."},{"key":"e_1_3_2_379_2","unstructured":". 2011. Benlysta (belimumab). Full prescribing information. Reference ID 4281596. Food and Drug Administration Silver Spring MD."},{"key":"e_1_3_2_380_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm5120107"},{"key":"e_1_3_2_381_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31817-3"},{"key":"e_1_3_2_382_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517740641"},{"key":"e_1_3_2_383_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-019-02635-9"},{"key":"e_1_3_2_384_2","unstructured":". 2003. Bexxar (tositumomab and iodine I 131 tositumomab). Full prescribing information. Food and Drug Administration Silver Spring MD. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/125011s102lbl.pdf."},{"key":"e_1_3_2_385_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041511"},{"key":"e_1_3_2_386_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190902730219"},{"key":"e_1_3_2_387_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn478"},{"key":"e_1_3_2_388_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-317"},{"key":"e_1_3_2_389_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02785.x"},{"key":"e_1_3_2_390_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2007.00700.x"},{"key":"e_1_3_2_391_2","doi-asserted-by":"publisher","DOI":"10.6002\/ect.2014.0156"},{"key":"e_1_3_2_392_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22025"},{"key":"e_1_3_2_393_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032534"},{"key":"e_1_3_2_394_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel358"},{"key":"e_1_3_2_395_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21778"},{"key":"e_1_3_2_396_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.083188"},{"key":"e_1_3_2_397_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150051"},{"key":"e_1_3_2_398_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21214"},{"key":"e_1_3_2_399_2","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/454897"},{"key":"e_1_3_2_400_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0106"},{"key":"e_1_3_2_401_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.56.7468"},{"key":"e_1_3_2_402_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.56.8233"},{"key":"e_1_3_2_403_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.0182"},{"key":"e_1_3_2_404_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastrohep.2014.05.008"},{"key":"e_1_3_2_405_2","doi-asserted-by":"publisher","DOI":"10.1002\/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0"},{"key":"e_1_3_2_406_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25253"},{"key":"e_1_3_2_407_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701411441"},{"key":"e_1_3_2_408_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-163493"},{"key":"e_1_3_2_409_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-010-0331-4"},{"key":"e_1_3_2_410_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq583"},{"key":"e_1_3_2_411_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(91)90599-G"},{"key":"e_1_3_2_412_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19961115)78:10<2210::AID-CNCR24>3.0.CO;2-0"},{"key":"e_1_3_2_413_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.07.006"},{"key":"e_1_3_2_414_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-011-1241-0"},{"key":"e_1_3_2_415_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.7081"},{"key":"e_1_3_2_416_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.18.2010"},{"key":"e_1_3_2_417_2","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/945950"},{"key":"e_1_3_2_418_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29344"},{"key":"e_1_3_2_419_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-289231"},{"key":"e_1_3_2_420_2","doi-asserted-by":"publisher","DOI":"10.1177\/0956462416675109"},{"key":"e_1_3_2_421_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1437"},{"key":"e_1_3_2_422_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06943.x"},{"key":"e_1_3_2_423_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-231613"},{"key":"e_1_3_2_424_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-498964"},{"key":"e_1_3_2_425_2","doi-asserted-by":"publisher","DOI":"10.1159\/000456036"},{"key":"e_1_3_2_426_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-186999"},{"key":"e_1_3_2_427_2","doi-asserted-by":"publisher","DOI":"10.1177\/2042098612453849"},{"key":"e_1_3_2_428_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13365-018-0615-7"},{"key":"e_1_3_2_429_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.01.002"},{"key":"e_1_3_2_430_2","doi-asserted-by":"publisher","DOI":"10.1159\/000354828"},{"key":"e_1_3_2_431_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815039"},{"key":"e_1_3_2_432_2","doi-asserted-by":"publisher","DOI":"10.1177\/030089160909500123"},{"key":"e_1_3_2_433_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200109273451315"},{"key":"e_1_3_2_434_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-005-1038-0"},{"key":"e_1_3_2_435_2","first-page":"498","article-title":"Case report: severe CMV colitis in a patient with follicular lymphoma after chemotherapy","volume":"94","author":"Polprasert C","year":"2011","unstructured":"Polprasert C, Wongjitrat C, Wisedopas N. 2011. Case report: severe CMV colitis in a patient with follicular lymphoma after chemotherapy. J Med Assoc Thai 94:498\u2013500.","journal-title":"J Med Assoc Thai"},{"key":"e_1_3_2_436_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1214855"},{"key":"e_1_3_2_437_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.4.1486"},{"key":"e_1_3_2_438_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.6467"},{"key":"e_1_3_2_439_2","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2012-006672"},{"key":"e_1_3_2_440_2","doi-asserted-by":"publisher","DOI":"10.1097\/NRL.0b013e318287fde0"},{"key":"e_1_3_2_441_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.798867"},{"key":"e_1_3_2_442_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100818"},{"key":"e_1_3_2_443_2","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2016.1202318"},{"key":"e_1_3_2_444_2","first-page":"65","article-title":"Cytomegalovirus infection in non-transplant patients with hematologic neoplasms: a case series","volume":"34","author":"Chang H","year":"2011","unstructured":"Chang H, Tang TC, Hung YS, Lin TL, Kuo MC, Wang PN. 2011. Cytomegalovirus infection in non-transplant patients with hematologic neoplasms: a case series. Chang Gung Med J 34:65\u201374.","journal-title":"Chang Gung Med J"},{"key":"e_1_3_2_445_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2453"},{"key":"e_1_3_2_446_2","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-9-36"},{"key":"e_1_3_2_447_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLML.2010.n.017"},{"key":"e_1_3_2_448_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-007-0397-0"},{"key":"e_1_3_2_449_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2009.00903.x"},{"key":"e_1_3_2_450_2","first-page":"573","article-title":"Effects of low-dose rituximab therapy in patients with primary cytomegalovirus infection","volume":"13","author":"Ishihara H","year":"2015","unstructured":"Ishihara H, Ishida H, Toki D, Omoto K, Sirakawa H, Shimizu T, Okumi M, Tanabe K. 2015. Effects of low-dose rituximab therapy in patients with primary cytomegalovirus infection. Exp Clin Transplant 13:573\u2013580.","journal-title":"Exp Clin Transplant"},{"key":"e_1_3_2_451_2","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2014.948981"},{"key":"e_1_3_2_452_2","first-page":"894","article-title":"Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma","volume":"85","author":"Bermudez A","year":"2000","unstructured":"Bermudez A, Marco F, Conde E, Mazo E, Recio M, Zubizarreta A. 2000. Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica 85:894\u2013895.","journal-title":"Haematologica"},{"key":"e_1_3_2_453_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2257.2001.00397.x"},{"key":"e_1_3_2_454_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep14008"},{"key":"e_1_3_2_455_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.27233"},{"key":"e_1_3_2_456_2","doi-asserted-by":"publisher","DOI":"10.5402\/2013\/819025"},{"key":"e_1_3_2_457_2","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1429"},{"key":"e_1_3_2_458_2","doi-asserted-by":"publisher","DOI":"10.1188\/14.ONF.327-330"},{"key":"e_1_3_2_459_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-011-1238-8"},{"key":"e_1_3_2_460_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3379-6"},{"key":"e_1_3_2_461_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.3.1184.015k54_1184_1186"},{"key":"e_1_3_2_462_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2006.05.002"},{"key":"e_1_3_2_463_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2005.n.053"},{"key":"e_1_3_2_464_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv136"},{"key":"e_1_3_2_465_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2009.01044.x"},{"key":"e_1_3_2_466_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-364"},{"key":"e_1_3_2_467_2","first-page":"461","article-title":"Infectious complications of a rituximab-based immunosuppressive regimen in patients with glomerular disease","volume":"10","author":"Trivin C","year":"2017","unstructured":"Trivin C, Tran A, Moulin B, Choukroun G, Gatault P, Courivaud C, Augusto J-F, Ficheux M, Vigneau C, Thervet E, Karras A. 2017. Infectious complications of a rituximab-based immunosuppressive regimen in patients with glomerular disease. Clin Kidney J 10:461\u2013469.","journal-title":"Clin Kidney J"},{"key":"e_1_3_2_468_2","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s10067-014-2509-2","article-title":"Risk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab","volume":"33","author":"Heusele M","year":"2014","unstructured":"Heusele M, Clerson P, Guery B, Lambert M, Launay D, Lefevre G, Morell-Dubois S, Maillard H, Le Gouellec N, Hatron P-Y, Hachulla E. 2014. Risk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab. Clin Rheumatol 33:799\u2013805.","journal-title":"Clin Rheumatol"},{"key":"e_1_3_2_469_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2012.10.018"},{"key":"e_1_3_2_470_2","doi-asserted-by":"publisher","DOI":"10.11406\/rinketsu.57.597"},{"key":"e_1_3_2_471_2","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/8909834"},{"key":"e_1_3_2_472_2","doi-asserted-by":"publisher","DOI":"10.2174\/1874312901206010286"},{"key":"e_1_3_2_473_2","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2012-006585"},{"key":"e_1_3_2_474_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.27555"},{"key":"e_1_3_2_475_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken143"},{"key":"e_1_3_2_476_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2005.05.007"},{"key":"e_1_3_2_477_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.144998"},{"key":"e_1_3_2_478_2","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2010.25.1.86"},{"key":"e_1_3_2_479_2","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181fa941b"},{"key":"e_1_3_2_480_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2008.02411.x"},{"key":"e_1_3_2_481_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2008.00902.x"},{"key":"e_1_3_2_482_2","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181a235fd"},{"key":"e_1_3_2_483_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-0477"},{"key":"e_1_3_2_484_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190903258780"},{"key":"e_1_3_2_485_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.03099-14"},{"key":"e_1_3_2_486_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122171"},{"key":"e_1_3_2_487_2","doi-asserted-by":"publisher","DOI":"10.1086\/525852"},{"key":"e_1_3_2_488_2","doi-asserted-by":"publisher","DOI":"10.2459\/JCM.0000000000000160"},{"key":"e_1_3_2_489_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2012.07.011"},{"key":"e_1_3_2_490_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1411.080003"},{"key":"e_1_3_2_491_2","first-page":"1683","article-title":"Severe nontuberculous mycobacterial infection in 2 patients receiving rituximab for refractory myositis","volume":"35","author":"Lutt JR","year":"2008","unstructured":"Lutt JR, Pisculli ML, Weinblatt ME, Deodhar A, Winthrop KL. 2008. Severe nontuberculous mycobacterial infection in 2 patients receiving rituximab for refractory myositis. J Rheumatol 35:1683\u20131685.","journal-title":"J Rheumatol"},{"key":"e_1_3_2_492_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker210"},{"key":"e_1_3_2_493_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2257.2006.00751.x"},{"key":"e_1_3_2_494_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190902782210"},{"key":"e_1_3_2_495_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002770100346"},{"key":"e_1_3_2_496_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx204"},{"key":"e_1_3_2_497_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0036-46652010000400011"},{"key":"e_1_3_2_498_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61649-8"},{"key":"e_1_3_2_499_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60508-X"},{"key":"e_1_3_2_500_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277"},{"key":"e_1_3_2_501_2","doi-asserted-by":"crossref","first-page":"S31.004","DOI":"10.1212\/WNL.88.16_supplement.S31.004","article-title":"Preliminary Results of the OPERA I and OPERA II open-label extension study","volume":"88","author":"500.","year":"2017","unstructured":"500.Naismith R, Cascione M, Grimaldi LM, Hauser S, Kappos L, Montalban X, Wolinsky J, Chin P, Garren H, Julian L, Model F, Honeycutt D. 2017. Preliminary Results of the OPERA I and OPERA II open-label extension study. Neurology 88(16 Suppl):S31.004.","journal-title":"Neurology"},{"key":"e_1_3_2_502_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-111781"},{"key":"e_1_3_2_503_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.3187"},{"key":"e_1_3_2_504_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"e_1_3_2_505_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-323980"},{"key":"e_1_3_2_506_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984"},{"key":"e_1_3_2_507_2","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2017_320"},{"key":"e_1_3_2_508_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614598"},{"key":"e_1_3_2_509_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203312469259"},{"key":"e_1_3_2_510_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-013-0074-x"},{"key":"e_1_3_2_511_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61354-2"},{"key":"e_1_3_2_512_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.30613"},{"key":"e_1_3_2_513_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.34564"},{"key":"e_1_3_2_514_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121368"},{"key":"e_1_3_2_515_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.3745"},{"key":"e_1_3_2_516_2","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.50160"},{"key":"e_1_3_2_517_2","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2016.0024"},{"key":"e_1_3_2_518_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.04.015"},{"key":"e_1_3_2_519_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20110"},{"key":"e_1_3_2_520_2","doi-asserted-by":"publisher","DOI":"10.1086\/315147"},{"key":"e_1_3_2_521_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.15704"},{"key":"e_1_3_2_522_2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2014.870473"},{"key":"e_1_3_2_523_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1297-319X(08)73620-0"},{"key":"e_1_3_2_524_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-494096"},{"key":"e_1_3_2_525_2","unstructured":". 2001. Lemtrada (alemtuzumab). Full prescribing information. Reference ID 4163684. Food and Drug Administration Silver Spring MD."},{"key":"e_1_3_2_526_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2011-300826"},{"key":"e_1_3_2_527_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-012-0159-0"},{"key":"e_1_3_2_528_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.9098"},{"key":"e_1_3_2_529_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.1.205"},{"key":"e_1_3_2_530_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2802"},{"key":"e_1_3_2_531_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-352328"},{"key":"e_1_3_2_532_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.146"},{"key":"e_1_3_2_533_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.04.002"},{"key":"e_1_3_2_534_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24188"},{"key":"e_1_3_2_535_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02856.x"},{"key":"e_1_3_2_536_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61095-3"},{"key":"e_1_3_2_537_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40893-016-0011-1"},{"key":"e_1_3_2_538_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy174"},{"key":"e_1_3_2_539_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.659735"},{"key":"e_1_3_2_540_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v17.i34.3881"},{"key":"e_1_3_2_541_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.02.003"},{"key":"e_1_3_2_542_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2055-6640(20)30694-4"},{"key":"e_1_3_2_543_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001540"},{"key":"e_1_3_2_544_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802670"},{"key":"e_1_3_2_545_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61769-3"},{"key":"e_1_3_2_546_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517693440"},{"key":"e_1_3_2_547_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2017.03.001"},{"key":"e_1_3_2_548_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-080010"},{"key":"e_1_3_2_549_2","first-page":"1672","article-title":"Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation","volume":"90","author":"Ng AP","year":"2005","unstructured":"Ng AP, Worth L, Chen L, Seymour JF, Prince HM, Slavin M, Thursky K. 2005. Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation. Haematologica 90:1672\u20131679.","journal-title":"Haematologica"},{"key":"e_1_3_2_550_2","first-page":"232","article-title":"Guidelines for alemtuzumab treatment in chronic lymphocytic leukaemia (CLL)","volume":"58","author":"Smolej L","year":"2012","unstructured":"Smolej L, Prochazka V, Spacek M, Obrtlikova P, Gumulec J, Vokurka S, Doubek M. 2012. Guidelines for alemtuzumab treatment in chronic lymphocytic leukaemia (CLL). Vnitr Lek 58:232\u2013236. (In Czech.)","journal-title":"Vnitr Lek"},{"key":"e_1_3_2_551_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-016-0394-8"},{"key":"e_1_3_2_552_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0739-z"},{"key":"e_1_3_2_553_2","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-217998"},{"key":"e_1_3_2_554_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2007.06.010"},{"key":"e_1_3_2_555_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2007.00292.x"},{"key":"e_1_3_2_556_2","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S134398"},{"key":"e_1_3_2_557_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit816"},{"key":"e_1_3_2_558_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.09.031"},{"key":"e_1_3_2_559_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2017.08.051"},{"key":"e_1_3_2_560_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.0146"},{"key":"e_1_3_2_561_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517694431"},{"key":"e_1_3_2_562_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-017-0848-8"},{"key":"e_1_3_2_563_2","unstructured":". 2014. Blincyto (blinatumomab). Full prescribing information. Reference ID 4123274. Food and Drug Administration Silver Spring MD."},{"key":"e_1_3_2_564_2","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.64"},{"key":"e_1_3_2_565_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"e_1_3_2_566_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0343-9"},{"key":"e_1_3_2_567_2","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2018.029"},{"key":"e_1_3_2_568_2","unstructured":". 2015. Darzalex (daratumumab). Full prescribing information. Reference ID 4016996. Food and Drug Administration Silver Spring MD."},{"key":"e_1_3_2_569_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"key":"e_1_3_2_570_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607751"},{"key":"e_1_3_2_571_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.03.022"},{"key":"e_1_3_2_572_2","doi-asserted-by":"publisher","DOI":"10.1177\/2040620716652862"},{"key":"e_1_3_2_573_2","unstructured":". 2015. Empliciti (elotuzumab). Full prescribing information. Reference ID 3853154. Food and Drug Administration Silver Spring MD."},{"key":"e_1_3_2_574_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-0483"},{"key":"e_1_3_2_575_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4246"},{"key":"e_1_3_2_576_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505654"},{"key":"e_1_3_2_577_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.28.28"},{"key":"e_1_3_2_578_2","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12621"},{"key":"e_1_3_2_579_2","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000361"},{"key":"e_1_3_2_580_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.00050"},{"key":"e_1_3_2_581_2","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12620"},{"key":"e_1_3_2_582_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI93537"},{"key":"e_1_3_2_583_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri2691"},{"key":"e_1_3_2_584_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2"},{"key":"e_1_3_2_585_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00094-8"},{"key":"e_1_3_2_586_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1714635"},{"key":"e_1_3_2_587_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706314"},{"key":"e_1_3_2_588_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.02.002"},{"key":"e_1_3_2_589_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23687"},{"key":"e_1_3_2_590_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108936"},{"key":"e_1_3_2_591_2","first-page":"668","article-title":"Efficacy and safety of canakinumab in patients with Still\u2019s disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups","volume":"36","author":"Feist E","year":"2018","unstructured":"Feist E, Quartier P, Fautrel B, Schneider R, Sfriso P, Efthimiou P, Cantarini L, Lheritier K, Leon K, Karyekar CS, Speziale A. 2018. Efficacy and safety of canakinumab in patients with Still\u2019s disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups. Clin Exp Rheumatol 36:668\u2013675.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_2_592_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2013.10.008"},{"key":"e_1_3_2_593_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e318190cfb7"},{"key":"e_1_3_2_594_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3688-4"},{"key":"e_1_3_2_595_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-061512-150641"},{"key":"e_1_3_2_596_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-018-4041-1"},{"key":"e_1_3_2_597_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1462-2"},{"key":"e_1_3_2_598_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.02.006"},{"key":"e_1_3_2_599_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1756-185X.2011.01629.x"},{"key":"e_1_3_2_600_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200908"},{"key":"e_1_3_2_601_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009993"},{"key":"e_1_3_2_602_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3506-4"},{"key":"e_1_3_2_603_2","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12732"},{"key":"e_1_3_2_604_2","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e31826149a2"},{"key":"e_1_3_2_605_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-018-1842-x"},{"key":"e_1_3_2_606_2","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvx018"},{"key":"e_1_3_2_607_2","doi-asserted-by":"publisher","DOI":"10.7326\/L15-5107"},{"key":"e_1_3_2_608_2","doi-asserted-by":"publisher","DOI":"10.1159\/000326112"},{"key":"e_1_3_2_609_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707914"},{"key":"e_1_3_2_610_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32814-3"},{"key":"e_1_3_2_611_2","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2017.1421233"},{"key":"e_1_3_2_612_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar4159"},{"key":"e_1_3_2_613_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.27600"},{"key":"e_1_3_2_614_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10141"},{"key":"e_1_3_2_615_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.048371"},{"key":"e_1_3_2_616_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10578"},{"key":"e_1_3_2_617_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007848"},{"key":"e_1_3_2_618_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205099"},{"key":"e_1_3_2_619_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213150"},{"key":"e_1_3_2_620_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S73428"},{"key":"e_1_3_2_621_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810787"},{"key":"e_1_3_2_622_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.38777"},{"key":"e_1_3_2_623_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.152728"},{"key":"e_1_3_2_624_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-209031"},{"key":"e_1_3_2_625_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.40146"},{"key":"e_1_3_2_626_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew208"},{"key":"e_1_3_2_627_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204877"},{"key":"e_1_3_2_628_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket415"},{"key":"e_1_3_2_629_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-157-8-201210160-00003"},{"key":"e_1_3_2_630_2","first-page":"1102","article-title":"Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23)","volume":"59","year":"2010","unstructured":". 2010. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 59:1102\u20131106.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_2_631_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.137216"},{"key":"e_1_3_2_632_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex185"},{"key":"e_1_3_2_633_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2015.05.023"},{"key":"e_1_3_2_634_2","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0254"},{"key":"e_1_3_2_635_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2015.05.018"},{"key":"e_1_3_2_636_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2015.05.014"},{"key":"e_1_3_2_637_2","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.1096"},{"key":"e_1_3_2_638_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16317"},{"key":"e_1_3_2_639_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31191-1"},{"key":"e_1_3_2_640_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314768"},{"key":"e_1_3_2_641_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610020"},{"key":"e_1_3_2_642_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00388-8"},{"key":"e_1_3_2_643_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804093"},{"key":"e_1_3_2_644_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804092"},{"key":"e_1_3_2_645_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0702-4"},{"key":"e_1_3_2_646_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30307-5"},{"key":"e_1_3_2_647_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304048"},{"key":"e_1_3_2_648_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1806037"},{"key":"e_1_3_2_649_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.11.051"},{"key":"e_1_3_2_650_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.19330"},{"key":"e_1_3_2_651_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31881-1"},{"key":"e_1_3_2_652_2","unstructured":"Reference deleted."},{"key":"e_1_3_2_653_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.09.042"},{"key":"e_1_3_2_654_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2017.11.031"},{"key":"e_1_3_2_655_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.09.052"},{"key":"e_1_3_2_656_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2017.06.017"},{"key":"e_1_3_2_657_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2018.01.034"},{"key":"e_1_3_2_658_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature12526"},{"key":"e_1_3_2_659_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20051615"},{"key":"e_1_3_2_660_2","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2016.1208564"},{"key":"e_1_3_2_661_2","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevImmunol.2017020172"},{"key":"e_1_3_2_662_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.180318697"},{"key":"e_1_3_2_663_2","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12187"},{"key":"e_1_3_2_664_2","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000251"},{"key":"e_1_3_2_665_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1500871"},{"key":"e_1_3_2_666_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.11.5359"},{"key":"e_1_3_2_667_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2017.03.020"},{"key":"e_1_3_2_668_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.95"},{"key":"e_1_3_2_669_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2006.00784.x"},{"key":"e_1_3_2_670_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200711-1754OC"},{"key":"e_1_3_2_671_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708208"},{"key":"e_1_3_2_672_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702079"},{"key":"e_1_3_2_673_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.12.004"},{"key":"e_1_3_2_674_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070812"},{"key":"e_1_3_2_675_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2755"},{"key":"e_1_3_2_676_2","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/8163803"},{"key":"e_1_3_2_677_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri2273"},{"key":"e_1_3_2_678_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.176.2.469"},{"key":"e_1_3_2_679_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.03.044"},{"key":"e_1_3_2_680_2","doi-asserted-by":"publisher","DOI":"10.4137\/CCRPM.S7793"},{"key":"e_1_3_2_681_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601476"},{"key":"e_1_3_2_682_2","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1513\/AnnalsATS.201506-377AW","article-title":"The role of type 2 inflammation in the pathogenesis of asthma exacerbations","volume":"12","author":"Dunican EM","year":"2015","unstructured":"Dunican EM, Fahy JV. 2015. The role of type 2 inflammation in the pathogenesis of asthma exacerbations. Ann Am Thorac Soc 12(Suppl 2):S144\u2013S149.","journal-title":"Ann Am Thorac Soc"},{"key":"e_1_3_2_683_2","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.11546.1"},{"key":"e_1_3_2_684_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2017.09.003"},{"key":"e_1_3_2_685_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.08.050"},{"key":"e_1_3_2_686_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.155.6.9196082"},{"key":"e_1_3_2_687_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-015-9798-5"},{"key":"e_1_3_2_688_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200208-789OC"},{"key":"e_1_3_2_689_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010834.pub3"},{"key":"e_1_3_2_690_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808991"},{"key":"e_1_3_2_691_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805435"},{"key":"e_1_3_2_692_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60988-X"},{"key":"e_1_3_2_693_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31324-1"},{"key":"e_1_3_2_694_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(14)70187-0"},{"key":"e_1_3_2_695_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.03.032"},{"key":"e_1_3_2_696_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(15)00042-9"},{"key":"e_1_3_2_697_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201103-0396OC"},{"key":"e_1_3_2_698_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.03.018"},{"key":"e_1_3_2_699_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(14)70201-2"},{"key":"e_1_3_2_700_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2014.09.036"},{"key":"e_1_3_2_701_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31322-8"},{"key":"e_1_3_2_702_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(17)30190-X"},{"key":"e_1_3_2_703_2","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12853"},{"key":"e_1_3_2_704_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2017.04.002"},{"key":"e_1_3_2_705_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.05.031"},{"key":"e_1_3_2_706_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2017.01.013"},{"key":"e_1_3_2_707_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.05.044"},{"key":"e_1_3_2_708_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI84144"},{"key":"e_1_3_2_709_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.155.6.9196083"},{"key":"e_1_3_2_710_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.125.4.1378"},{"key":"e_1_3_2_711_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.117880"},{"key":"e_1_3_2_712_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-154-9-201105030-00002"},{"key":"e_1_3_2_713_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2004.1916.x"},{"key":"e_1_3_2_714_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01501-2015"},{"key":"e_1_3_2_715_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2016.11.006"},{"key":"e_1_3_2_716_2","doi-asserted-by":"publisher","DOI":"10.1111\/all.12169"},{"key":"e_1_3_2_717_2","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb.13.3.7654390"},{"key":"e_1_3_2_718_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.152.2.7633694"},{"key":"e_1_3_2_719_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.116576"},{"key":"e_1_3_2_720_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201611-2234OC"},{"key":"e_1_3_2_721_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015933"},{"key":"e_1_3_2_722_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00931-10"},{"key":"e_1_3_2_723_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.182.3.1577"},{"key":"e_1_3_2_724_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.07.055"},{"key":"e_1_3_2_725_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290"},{"key":"e_1_3_2_726_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.07.010"},{"key":"e_1_3_2_727_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003559"},{"key":"e_1_3_2_728_2","doi-asserted-by":"publisher","DOI":"10.3109\/9780203421703"},{"key":"e_1_3_2_729_2","first-page":"199","article-title":"Echinococcus multilocularis infection in a patient treated with omalizumab","volume":"23","author":"Skiepko R","year":"2013","unstructured":"Skiepko R, Zietkowski Z, Skiepko U, Tomasiak-Lozowska MM, Bodzenta-Lukaszyk A. 2013. Echinococcus multilocularis infection in a patient treated with omalizumab. J Invest Allergol Clin Immunol 23:199\u2013200.","journal-title":"J Invest Allergol Clin Immunol"},{"key":"e_1_3_2_730_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2007.02650.x"},{"key":"e_1_3_2_731_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2007.01601.x"},{"key":"e_1_3_2_732_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2017.11.007"},{"key":"e_1_3_2_733_2","doi-asserted-by":"publisher","DOI":"10.4103\/atm.ATM_231_16"},{"key":"e_1_3_2_734_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2016.11.019"},{"key":"e_1_3_2_735_2","doi-asserted-by":"publisher","DOI":"10.2500\/ar.2015.6.0128"},{"key":"e_1_3_2_736_2","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e328364b578"},{"key":"e_1_3_2_737_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.17.1.208-217.2004"},{"key":"e_1_3_2_738_2","doi-asserted-by":"publisher","DOI":"10.4103\/0255-0857.81797"},{"key":"e_1_3_2_739_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.02.00278102"},{"key":"e_1_3_2_740_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62170-9"},{"key":"e_1_3_2_741_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2004.00533.x"},{"key":"e_1_3_2_742_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009705"},{"key":"e_1_3_2_743_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.23.2956"},{"key":"e_1_3_2_744_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.121949"},{"key":"e_1_3_2_745_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-1241-3_8"},{"key":"e_1_3_2_746_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj2650621"},{"key":"e_1_3_2_747_2","doi-asserted-by":"publisher","DOI":"10.2174\/1381612821666150310143332"},{"key":"e_1_3_2_748_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.bor.0000218949.19860.d1"},{"key":"e_1_3_2_749_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V74.5.1704.1704"},{"key":"e_1_3_2_750_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.73.5.2751-2757.2005"},{"key":"e_1_3_2_751_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.963"},{"key":"e_1_3_2_752_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.01.006"},{"key":"e_1_3_2_753_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000145"},{"key":"e_1_3_2_754_2","doi-asserted-by":"publisher","DOI":"10.1023\/a:1011401825680"},{"key":"e_1_3_2_755_2","doi-asserted-by":"publisher","DOI":"10.1080\/08820139.2018.1480034"},{"key":"e_1_3_2_756_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcle.2017.10.022"},{"key":"e_1_3_2_757_2","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1093722"},{"key":"e_1_3_2_758_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2018.09.034"},{"key":"e_1_3_2_759_2","doi-asserted-by":"publisher","DOI":"10.5301\/jn.5000169"},{"key":"e_1_3_2_760_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-015-0135-z"},{"key":"e_1_3_2_761_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-015-0284-z"},{"key":"e_1_3_2_762_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00430-006-0019-9"},{"key":"e_1_3_2_763_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2011.12.032"},{"key":"e_1_3_2_764_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0829-7"},{"key":"e_1_3_2_765_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23940"},{"key":"e_1_3_2_766_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60453-5"},{"key":"e_1_3_2_767_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100717"},{"key":"e_1_3_2_768_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101920"},{"key":"e_1_3_2_769_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.01.012"},{"key":"e_1_3_2_770_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.27221"},{"key":"e_1_3_2_771_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10620"},{"key":"e_1_3_2_772_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3470"},{"key":"e_1_3_2_773_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23868"},{"key":"e_1_3_2_774_2","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.4"},{"key":"e_1_3_2_775_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key121"},{"key":"e_1_3_2_776_2","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X17752037"},{"key":"e_1_3_2_777_2","doi-asserted-by":"publisher","DOI":"10.1177\/2040620716653745"},{"key":"e_1_3_2_778_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq343"},{"key":"e_1_3_2_779_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120687"},{"key":"e_1_3_2_780_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214367"},{"key":"e_1_3_2_781_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.091220"},{"key":"e_1_3_2_782_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-011-2060-2"},{"key":"e_1_3_2_783_2","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2018.59.3.452"},{"key":"e_1_3_2_784_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130466"},{"key":"e_1_3_2_785_2","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-009-0243-4"},{"key":"e_1_3_2_786_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100737"},{"key":"e_1_3_2_787_2","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12081"},{"key":"e_1_3_2_788_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2015.07.009"},{"key":"e_1_3_2_789_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri3707"},{"key":"e_1_3_2_790_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3895"},{"key":"e_1_3_2_791_2","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2018.1506764"},{"key":"e_1_3_2_792_2","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S177127"},{"key":"e_1_3_2_793_2","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000457"},{"key":"e_1_3_2_794_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1395806"},{"key":"e_1_3_2_795_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.12.017"},{"key":"e_1_3_2_796_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy200"},{"key":"e_1_3_2_797_2","doi-asserted-by":"publisher","DOI":"10.3109\/1547691X.2015.1115448"},{"key":"e_1_3_2_798_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025038"},{"key":"e_1_3_2_799_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501646"},{"key":"e_1_3_2_800_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.01.025"},{"key":"e_1_3_2_801_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041"},{"key":"e_1_3_2_802_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.042"},{"key":"e_1_3_2_803_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.01.018"},{"key":"e_1_3_2_804_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30570-6"},{"key":"e_1_3_2_805_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31713-6"},{"key":"e_1_3_2_806_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30233-4"},{"key":"e_1_3_2_807_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213328"},{"key":"e_1_3_2_808_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607017"},{"key":"e_1_3_2_809_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31279-5"},{"key":"e_1_3_2_810_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200324038"},{"key":"e_1_3_2_811_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.280.5368.1435"},{"key":"e_1_3_2_812_2","doi-asserted-by":"publisher","DOI":"10.1111\/imcb.12210"},{"key":"e_1_3_2_813_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2014.09.008"},{"key":"e_1_3_2_814_2","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2016.71"},{"key":"e_1_3_2_815_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301668"},{"key":"e_1_3_2_816_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1618300114"},{"key":"e_1_3_2_817_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60725-4"},{"key":"e_1_3_2_818_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60726-6"},{"key":"e_1_3_2_819_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810652"},{"key":"e_1_3_2_820_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2011.01347.x"},{"key":"e_1_3_2_821_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062382"},{"key":"e_1_3_2_822_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2011.05.005"},{"key":"e_1_3_2_823_2","first-page":"166","article-title":"Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS)","volume":"12","author":"Zhu X","year":"2013","unstructured":"Zhu X, Zheng M, Song M, Shen YK, Chan D, Szapary PO, Wang B. 2013. Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS). J Drugs Dermatol 12:166\u2013174.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_2_824_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60140-9"},{"key":"e_1_3_2_825_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60594-2"},{"key":"e_1_3_2_826_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204655"},{"key":"e_1_3_2_827_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204741"},{"key":"e_1_3_2_828_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203572"},{"key":"e_1_3_2_829_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007572"},{"key":"e_1_3_2_830_2","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000842"},{"key":"e_1_3_2_831_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602773"},{"key":"e_1_3_2_832_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11142.x"},{"key":"e_1_3_2_833_2","doi-asserted-by":"publisher","DOI":"10.1111\/ced.12390"},{"key":"e_1_3_2_834_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.06.041"},{"key":"e_1_3_2_835_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.06.011"},{"key":"e_1_3_2_836_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12214"},{"key":"e_1_3_2_837_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.0718"},{"key":"e_1_3_2_838_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12461"},{"key":"e_1_3_2_839_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-018-0671-z"},{"key":"e_1_3_2_840_2","doi-asserted-by":"publisher","DOI":"10.1159\/000323736"},{"key":"e_1_3_2_841_2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12370"},{"key":"e_1_3_2_842_2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13755"},{"key":"e_1_3_2_843_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2018.1445193"},{"key":"e_1_3_2_844_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.0793"},{"key":"e_1_3_2_845_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15750"},{"key":"e_1_3_2_846_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30952-8"},{"key":"e_1_3_2_847_2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14294"},{"key":"e_1_3_2_848_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16724"},{"key":"e_1_3_2_849_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18232"},{"key":"e_1_3_2_850_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.adengl.2015.05.013"},{"key":"e_1_3_2_851_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12120"},{"key":"e_1_3_2_852_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12045"},{"key":"e_1_3_2_853_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.1.36"},{"key":"e_1_3_2_854_2","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2007.35"},{"key":"e_1_3_2_855_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri1807"},{"key":"e_1_3_2_856_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2127"},{"key":"e_1_3_2_857_2","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/3908061"},{"key":"e_1_3_2_858_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri2800"},{"key":"e_1_3_2_859_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.194.4.519"},{"key":"e_1_3_2_860_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20091669"},{"key":"e_1_3_2_861_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20091983"},{"key":"e_1_3_2_862_2","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0b013e328358cc0b"},{"key":"e_1_3_2_863_2","unstructured":"Kniffin C. 2015. Interleukin 17 receptor C; IL17RC. Alternative titles; symbols: Interleukin 17 receptor-like protein; IL17RL. OMIM Johns Hopkins University Baltimore MD. https:\/\/www.omim.org\/entry\/610925. Accessed 22 March 2019."},{"key":"e_1_3_2_864_2","unstructured":"Hamosh A. 2011. Candidiasis familial 6; CANDF6. Alternative titles; symbols: Candidiasis Familial Chronic Mucocutaneous Autosomal Dominant OMIM Johns Hopkins University Baltimore MD. https:\/\/www.omim.org\/entry\/613956. Accessed 22 March 2019."},{"key":"e_1_3_2_865_2","unstructured":"Kniffin C. 2015. Candidiasis familial 9; CANDF9. OMIM Johns Hopkins University Baltimore MD. https:\/\/www.omim.org\/entry\/616445. Accessed 22 March 2019."},{"key":"e_1_3_2_866_2","unstructured":"Kniffin C. 2000. Interleukin 17C; IL17C. OMIM. Johns Hopkins University Baltimore MD. https:\/\/www.omim.org\/entry\/604628. Accessed 22 March 2019."},{"key":"e_1_3_2_867_2","unstructured":"Kniffin C. 2000. Interleukin 17 receptor A; IL17RA. Alternative titles; symbols: IL17R. OMIM Johns Hopkins University Baltimore MD. https:\/\/www.omim.org\/entry\/605461. Accessed 22 March 2019."},{"key":"e_1_3_2_868_2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.144"},{"key":"e_1_3_2_869_2","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2017.34"},{"key":"e_1_3_2_870_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3742"},{"key":"e_1_3_2_871_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2017.12.006"},{"key":"e_1_3_2_872_2","first-page":"50","article-title":"Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the phase 3 MEASURE 1 trial","volume":"36","author":"Baraliakos X","year":"2018","unstructured":"Baraliakos X, Kivitz AJ, Deodhar AA, Braun J, Wei JC, Delicha EM, Talloczy Z, Porter B. 2018. Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the phase 3 MEASURE 1 trial. Clin Exp Rheumatol 36:50\u201355.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_2_873_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066"},{"key":"e_1_3_2_874_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31946-9"},{"key":"e_1_3_2_875_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.40070"},{"key":"e_1_3_2_876_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-016-3480-9"},{"key":"e_1_3_2_877_2","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2017.1390605"},{"key":"e_1_3_2_878_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.05.032"},{"key":"e_1_3_2_879_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key161"},{"key":"e_1_3_2_880_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"e_1_3_2_881_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14878"},{"key":"e_1_3_2_882_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex301"},{"key":"e_1_3_2_883_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15707"},{"key":"e_1_3_2_884_2","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13094"},{"key":"e_1_3_2_885_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23111"},{"key":"e_1_3_2_886_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412679"},{"key":"e_1_3_2_887_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5"},{"key":"e_1_3_2_888_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.08.024"},{"key":"e_1_3_2_889_2","first-page":"1","article-title":"Brodalumab: a review of safety","volume":"23","author":"Rusta-Sallehy S","year":"2018","unstructured":"Rusta-Sallehy S, Gooderham M, Papp K. 2018. Brodalumab: a review of safety. Skin Therapy Lett 23:1\u20133.","journal-title":"Skin Therapy Lett"},{"key":"e_1_3_2_890_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.08.057"},{"key":"e_1_3_2_891_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri2742"},{"key":"e_1_3_2_892_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs263"},{"key":"e_1_3_2_893_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.02.074"},{"key":"e_1_3_2_894_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14581"},{"key":"e_1_3_2_895_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.03.047"},{"key":"e_1_3_2_896_2","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2801"},{"key":"e_1_3_2_897_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15015"},{"key":"e_1_3_2_898_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2018.1530437"},{"key":"e_1_3_2_899_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.03.024"},{"key":"e_1_3_2_900_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.09.026"},{"key":"e_1_3_2_901_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.298"},{"key":"e_1_3_2_902_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.10.027"},{"key":"e_1_3_2_903_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.10.026"},{"key":"e_1_3_2_904_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503824"},{"key":"e_1_3_2_905_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14493"},{"key":"e_1_3_2_906_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14702"},{"key":"e_1_3_2_907_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315231"},{"key":"e_1_3_2_908_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109017"},{"key":"e_1_3_2_909_2","doi-asserted-by":"publisher","DOI":"10.2174\/138920009788897975"},{"key":"e_1_3_2_910_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.247"},{"key":"e_1_3_2_911_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-012-0767-5"},{"key":"e_1_3_2_912_2","first-page":"318","article-title":"The mechanism of action of tofacitinib\u2014an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis","volume":"34","author":"Hodge JA","year":"2016","unstructured":"Hodge JA, Kawabata TT, Krishnaswami S, Clark JD, Telliez JB, Dowty ME, Menon S, Lamba M, Zwillich S. 2016. The mechanism of action of tofacitinib\u2014an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 34:318\u2013328.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_2_913_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.34329"},{"key":"e_1_3_2_914_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203756"},{"key":"e_1_3_2_915_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2016.11.006"},{"key":"e_1_3_2_916_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003668"},{"key":"e_1_3_2_917_2","unstructured":". 2018. Xeljanz (tofacitinib). Prescribing information. Reference ID 4308396. Food and Drug Administration Silver Spring MD. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/203214s021 208246s007lbl.pdf. Accessed August 2019."},{"key":"e_1_3_2_918_2","unstructured":"European Medicines Agency. 2018. Xeljanz INN\u2014tofacitinib citrate. Product information. European Medicines Agency Amsterdam The Netherlands. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004214\/WC500224911.pdf. Accessed August 2019."},{"key":"e_1_3_2_919_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62113-9"},{"key":"e_1_3_2_920_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.01.053"},{"key":"e_1_3_2_921_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206478"},{"key":"e_1_3_2_922_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01510"},{"key":"e_1_3_2_923_2","unstructured":"European Medicines Agency. 2018. Olumiant INN\u2014baricitinib. Product information. European Medicines Agency Amsterdam The Netherlands. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004085\/WC500223723.pdf. Accessed August 2019."},{"key":"e_1_3_2_924_2","unstructured":"Therapeutic Goods Administration. 2018. Australian PI\u2014Olumiant (baricitinib). Therapeutic Goods Administration Woden Australia. https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2018-PI-01225-1. Accessed August 2019."},{"key":"e_1_3_2_925_2","unstructured":". 2018. Olumiant (baricitinib). Prescribing information. Reference ID 4271150. Food and Drug Administration Silver Spring MD. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/207924Orig1s000lbl.pdf. Accessed August 2019."},{"key":"e_1_3_2_926_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31363-1"},{"key":"e_1_3_2_927_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI98814"},{"key":"e_1_3_2_928_2","unstructured":"Therapeutic Goods Administration. 2018. Australian product information\u2014Jakavi (ruxolitinib). Therapeutic Goods Administration Woden Australia. https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2013-PI-01918-1&d=201809111016933. Accessed August 2019."},{"key":"e_1_3_2_929_2","unstructured":". 2018. Jakafi (ruxolitinib). Prescribing information. Reference ID 4191667. Food and Drug Administration Silver Spring MD. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/202192s015lbl.pdf. Accessed August 2019."},{"key":"e_1_3_2_930_2","unstructured":"European Medicines Agency. 2018. Jakavi INN\u2014ruxolitinib. Product information. European Medicines Agency Amsterdam The Netherlands. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002464\/WC500133223.pdf. Accessed August 2019."},{"key":"e_1_3_2_931_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_3_2_932_2","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e3181695687"},{"key":"e_1_3_2_933_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.9055"},{"key":"e_1_3_2_934_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32463-2"},{"key":"e_1_3_2_935_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32483-8"},{"key":"e_1_3_2_936_2","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2018.1442433"},{"key":"e_1_3_2_937_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.40680"},{"key":"e_1_3_2_938_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.38779"},{"key":"e_1_3_2_939_2","unstructured":". 2018. Shingrix (zoster vaccine recombinant adjuvanted). Prescribing information. Food and Drug Administration Silver Spring MD. https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM581605.pdf. Accessed September 2019."},{"key":"e_1_3_2_940_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2016.04.001"},{"key":"e_1_3_2_941_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.40187"},{"key":"e_1_3_2_942_2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1317410"},{"key":"e_1_3_2_943_2","doi-asserted-by":"publisher","DOI":"10.1080\/1744666x.2018.1504678"},{"key":"e_1_3_2_944_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.02.009"},{"key":"e_1_3_2_945_2","doi-asserted-by":"publisher","DOI":"10.1080\/23744235.2017.1390248"},{"key":"e_1_3_2_946_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.242909"},{"key":"e_1_3_2_947_2","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2018.1473030"},{"key":"e_1_3_2_948_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509981"},{"key":"e_1_3_2_949_2","unstructured":". 2018. Imbruvica (ibrutinib). Prescribing information. Reference ID 4222705. Food and Drug Administration Silver Spring MD. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210563s000lbl.pdf. Accessed August 2019."},{"key":"e_1_3_2_950_2","unstructured":"Therapeutic Goods Administration. 2018. Australian product information\u2014Imbruvica (ibrutinib). Therapeutic Goods Administration Woden Australia. https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2015-PI-01676-1&d=201808251016933. Accessed August 2019."},{"key":"e_1_3_2_951_2","unstructured":"European Medicines Agency. 2018. Imbruvica INN\u2014ibrutinib. Product information. European Medicines Agency Amsterdam The Netherlands. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003791\/WC500177775.pdf. Accessed August 2019."},{"key":"e_1_3_2_952_2","unstructured":". 2018. Calquence (acalabrutinib). Prescribing information. Reference ID 4174611. Acalabrutinib Food and Drug Administration Silver Spring MD. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/210259s000lbl.pdf. Accessed August 2019."},{"key":"e_1_3_2_953_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.03.004"},{"key":"e_1_3_2_954_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.04.007"},{"key":"e_1_3_2_955_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018013060"},{"key":"e_1_3_2_956_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy175"},{"key":"e_1_3_2_957_2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13020"},{"key":"e_1_3_2_958_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00465-9"},{"key":"e_1_3_2_959_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"e_1_3_2_960_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1948"},{"key":"e_1_3_2_961_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30632-5"},{"key":"e_1_3_2_962_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-747345"},{"key":"e_1_3_2_963_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.04.012"},{"key":"e_1_3_2_964_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2017.03.011"},{"key":"e_1_3_2_965_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1320710"},{"key":"e_1_3_2_966_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1600328"},{"key":"e_1_3_2_967_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix687"},{"key":"e_1_3_2_968_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-11-818286"},{"key":"e_1_3_2_969_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.830.830"},{"key":"e_1_3_2_970_2","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/4642831"},{"key":"e_1_3_2_971_2","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2018.836"},{"key":"e_1_3_2_972_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-2944-7"},{"key":"e_1_3_2_973_2","first-page":"424","article-title":"Occult HBV reactivation induced by ibrutinib treatment: a case report","volume":"78","author":"de Jesus Ngoma P","year":"2015","unstructured":"de Jesus Ngoma P, Kabamba B, Dahlqvist G, Sempoux C, Lanthier N, Shindano T, Van Den Neste E, Horsmans Y. 2015. Occult HBV reactivation induced by ibrutinib treatment: a case report. Acta Gastroenterol Belg 78:424\u2013426.","journal-title":"Acta Gastroenterol Belg"},{"key":"e_1_3_2_974_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2917-2"},{"key":"e_1_3_2_975_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-2964-3"},{"key":"e_1_3_2_976_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2385-0"},{"key":"e_1_3_2_977_2","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1099w"},{"key":"e_1_3_2_978_2","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/6514604"},{"key":"e_1_3_2_979_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy168"},{"key":"e_1_3_2_980_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1267352"},{"key":"e_1_3_2_981_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2387"},{"key":"e_1_3_2_982_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-722991"},{"key":"e_1_3_2_983_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24890"},{"key":"e_1_3_2_984_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.164103"},{"key":"e_1_3_2_985_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33108-2"},{"key":"e_1_3_2_986_2","first-page":"4326","article-title":"Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in hematologic malignancies","volume":"130","author":"Byrd JC","year":"2017","unstructured":"Byrd JC, Owen R, Brien SM, Brown JR, Hillmen P, Bitman B, Chernyukhin N, Hamdy A, Izumi R, Patel P, Schwartz-Sagi L, Tucker E, Fowler NH, Streetly MJ, Wiestner A, Rule S, Wang M. 2017. Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in hematologic malignancies. Blood 130:4326.","journal-title":"Blood"},{"key":"e_1_3_2_987_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15080"},{"key":"e_1_3_2_988_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.164285"},{"key":"e_1_3_2_989_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.2437"},{"key":"e_1_3_2_990_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14855"},{"key":"e_1_3_2_991_2","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S142264"},{"key":"e_1_3_2_992_2","first-page":"821","article-title":"PI3K inhibitors: understanding toxicity mechanisms and management","volume":"31","author":"Greenwell IB","year":"2017","unstructured":"Greenwell IB, Ip A, Cohen JB. 2017. PI3K inhibitors: understanding toxicity mechanisms and management. Oncology (Williston Park) 31:821\u2013828.","journal-title":"Oncology (Williston Park)"},{"key":"e_1_3_2_993_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-538546"},{"key":"e_1_3_2_994_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314583"},{"key":"e_1_3_2_995_2","unstructured":". 2018. Zydelig (idelalisib). Prescribing information. Reference ID 4213201. Food and Drug Administration Silver Spring MD. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/205858s009lbl.pdf. Accessed August 2019."},{"key":"e_1_3_2_996_2","unstructured":"European Medicines Agency. 2018. Zydelig INN\u2014idelalisib. Product information. European Medicines Agency Amsterdam The Netherlands. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003843\/WC500175377.pdf. Accessed August 2019."},{"key":"e_1_3_2_997_2","unstructured":"Therapeutic Goods Administration. 2018. Product information\u2014Zydelig (idelalisib). Therapeutic Goods Administration Woden Australia. https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2015-PI-01225-1&d=201809151016933. Accessed August 2019."},{"key":"e_1_3_2_998_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.187070"},{"key":"e_1_3_2_999_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-0993-T"},{"key":"e_1_3_2_1000_2","unstructured":". 2018. Aliqopa (copanlisib). Prescribing information. Reference ID 4152629. Food and Drug Administration Silver Spring MD. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209936s000lbl.pdf. Accessed August 2019."},{"key":"e_1_3_2_1001_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315226"},{"key":"e_1_3_2_1002_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30671-4"},{"key":"e_1_3_2_1003_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30019-4"},{"key":"e_1_3_2_1004_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1022770"},{"key":"e_1_3_2_1005_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.3705.3705"},{"key":"e_1_3_2_1006_2","unstructured":"Australian Government Department of Health. 2016. Idelalisib (zydelig) 100 mg and 150 mg tablets: monitoring communication\u2014risk of serious adverse events for specific patient groups in clinical trials. https:\/\/www.tga.gov.au\/monitoring-communication\/idelalisib-zydelig-100-mg-and-150-mg-tablets. Accessed 16 July 2019."},{"key":"e_1_3_2_1007_2","unstructured":"Australian Government Department of Health. 2017. Idelalisib (zydelig): safety advisory\u2014change to indications and addition of warnings. https:\/\/www.tga.gov.au\/alert\/idelalisib-zydelig. Accessed 12 July 2019."},{"key":"e_1_3_2_1008_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx289"},{"key":"e_1_3_2_1009_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.4648"},{"key":"e_1_3_2_1010_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2540"},{"key":"e_1_3_2_1011_2","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2016.00005"},{"key":"e_1_3_2_1012_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)30025-4"},{"key":"e_1_3_2_1013_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_3_2_1014_2","doi-asserted-by":"publisher","DOI":"10.1186\/1750-9378-8-23"},{"key":"e_1_3_2_1015_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441401"},{"key":"e_1_3_2_1016_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199907153410306"},{"key":"e_1_3_2_1017_2","unstructured":". 2018. Gleevec (imatinib mesylate). Prescribing information. Reference ID 4309490. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/021588s053lbl.pdf. Accessed September 2019."},{"key":"e_1_3_2_1018_2","unstructured":"European Medicines Agency. 2018. Zydelig INN\u2014imatinib. Product information. European Medicines Agency Amsterdam The Netherlands. https:\/\/www.ema.europa.eu\/documents\/product-information\/glivec-epar-product-information_en.pdf. Accessed September 2019."},{"key":"e_1_3_2_1019_2","unstructured":"Therapeutic Goods Administration. 2018. Australian product information\u2014Glivec (imatinib). Therapeutic Goods Administration Woden Australia. https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2010-PI-04296-3&d=201809271016933. Accessed September 2019."},{"key":"e_1_3_2_1020_2","unstructured":". 2018. Sprycel (dasatinib). Prescribing information. Reference ID 4179887. Food and Drug Administration Silver Spring MD. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021986s020lbl.pdf. Accessed September 2019."},{"key":"e_1_3_2_1021_2","unstructured":"Therapeutic Goods Administration. 2018. Australian product information\u2014Sprycel (dasatinib). Therapeutic Goods Administration Woden Australia. https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2010-PI-02657-3. Accessed September 2019."},{"key":"e_1_3_2_1022_2","unstructured":"European Medicines Agency. 2018. Sprycel INN\u2014dasatinib. Product information. European Medicines Agency Amsterdam The Netherlands. https:\/\/www.ema.europa.eu\/documents\/product-information\/sprycel-epar-product-information_en.pdf. Accessed September 2019."},{"key":"e_1_3_2_1023_2","unstructured":"Therapeutic Goods Administration. 2018. Australian product information\u2014Tasigna (nilotinib). Therapeutic Goods Administration Woden Australia. https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2009-PI-00292-3. Accessed September 2019."},{"key":"e_1_3_2_1024_2","unstructured":". 2018. Tasigna (nilotinib). Prescribing information. Reference ID 4309495. Food and Drug Administration Silver Spring MD. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/022068s029lbl.pdf. Accessed September 2019."},{"key":"e_1_3_2_1025_2","unstructured":"European Medicines Agency. 2018. Tasigna INN\u2014nilotinib. Product information. European Medicines Agency Amsterdam The Netherlands. https:\/\/www.ema.europa.eu\/documents\/product-information\/tasigna-epar-product-information_en.pdf. Accessed September 2019."},{"key":"e_1_3_2_1026_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205127"},{"key":"e_1_3_2_1027_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-355594"},{"key":"e_1_3_2_1028_2","unstructured":"European Medicines Agency. 2018. Bosulif INN\u2014bosutinib. Product information. European Medicines Agency Amsterdam The Netherlands. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002373\/WC500141721.pdf. Accessed August 2019."},{"key":"e_1_3_2_1029_2","unstructured":". 2018. Bosulif (bosutinib). Prescribing information. Reference ID 4197387. Food and Drug Administration Silver Spring MD. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/203341s009lbl.pdf. Accessed August 2019."},{"key":"e_1_3_2_1030_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-017-1105-1"},{"key":"e_1_3_2_1031_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190801896103"},{"key":"e_1_3_2_1032_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390120"},{"key":"e_1_3_2_1033_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2527"},{"key":"e_1_3_2_1034_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4266"},{"key":"e_1_3_2_1035_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0975"},{"key":"e_1_3_2_1036_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2008.05.002"},{"key":"e_1_3_2_1037_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2008.00234.x"},{"key":"e_1_3_2_1038_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-465039"},{"key":"e_1_3_2_1039_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07433.x"},{"key":"e_1_3_2_1040_2","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.31.5.1133"},{"key":"e_1_3_2_1041_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-017-2378-6"},{"key":"e_1_3_2_1042_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-084814"},{"key":"e_1_3_2_1043_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2008.02.006"},{"key":"e_1_3_2_1044_2","doi-asserted-by":"publisher","DOI":"10.1080\/14639230500236818"},{"key":"e_1_3_2_1045_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-009-0386-2"},{"key":"e_1_3_2_1046_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i8.1318"},{"key":"e_1_3_2_1047_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-008-9099-5"},{"key":"e_1_3_2_1048_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-015-1788-y"},{"key":"e_1_3_2_1049_2","first-page":"e86","article-title":"Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection","volume":"49","author":"Thia TJ","year":"2008","unstructured":"Thia TJ, Tan HH, Chuah TH, Chow WC, Lui HF. 2008. Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection. Singapore Med J 49:e86\u2013e89.","journal-title":"Singapore Med J"},{"key":"e_1_3_2_1050_2","doi-asserted-by":"publisher","DOI":"10.1080\/10245332.2017.1321882"},{"key":"e_1_3_2_1051_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1429"},{"key":"e_1_3_2_1052_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.10.039"},{"key":"e_1_3_2_1053_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_3_2_1054_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.3724"},{"key":"e_1_3_2_1055_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020461"},{"key":"e_1_3_2_1056_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.4452"},{"key":"e_1_3_2_1057_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4575"},{"key":"e_1_3_2_1058_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11665"},{"key":"e_1_3_2_1059_2","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2011.021"},{"key":"e_1_3_2_1060_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-016-0978-4"},{"key":"e_1_3_2_1061_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.05.019"},{"key":"e_1_3_2_1062_2","doi-asserted-by":"publisher","DOI":"10.1086\/498031"},{"key":"e_1_3_2_1063_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00025408"},{"key":"e_1_3_2_1064_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2008.581"},{"key":"e_1_3_2_1065_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.44.114"},{"key":"e_1_3_2_1066_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.9260"},{"key":"e_1_3_2_1067_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.011452"},{"key":"e_1_3_2_1068_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24423"},{"key":"e_1_3_2_1069_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"e_1_3_2_1070_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0772-3"},{"key":"e_1_3_2_1071_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2015.12.004"},{"key":"e_1_3_2_1072_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix325"},{"key":"e_1_3_2_1073_2","doi-asserted-by":"publisher","DOI":"10.4137\/CCRep.S25327"},{"key":"e_1_3_2_1074_2","doi-asserted-by":"publisher","DOI":"10.3947\/ic.2018.50.2.153"},{"key":"e_1_3_2_1075_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_3_2_1076_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.134"},{"key":"e_1_3_2_1077_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.270"},{"key":"e_1_3_2_1078_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26249"},{"key":"e_1_3_2_1079_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.323"},{"key":"e_1_3_2_1080_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V116.21.1233.1233"},{"key":"e_1_3_2_1081_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-013-1398-5"},{"key":"e_1_3_2_1082_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306494"},{"key":"e_1_3_2_1083_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00127-1"},{"key":"e_1_3_2_1084_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00080-2"},{"key":"e_1_3_2_1085_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24536"},{"key":"e_1_3_2_1086_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.7522"},{"key":"e_1_3_2_1087_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13108"},{"key":"e_1_3_2_1088_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23788"},{"key":"e_1_3_2_1089_2","unstructured":"European Medicines Agency. 2016. PRAC recommendations on signals. Adopted at the PRAC meeting of 8\u201311 February 2016. European Medicines Agency Amsterdam The Netherlands. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/PRAC_recommendation_on_signal\/2016\/02\/WC500202306.pdf. Accessed 23 July 2019."},{"key":"e_1_3_2_1090_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.09.013"},{"key":"e_1_3_2_1091_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800"},{"key":"e_1_3_2_1092_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1000500"},{"key":"e_1_3_2_1093_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-016-3482-7"},{"key":"e_1_3_2_1094_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.109058"},{"key":"e_1_3_2_1095_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-166439"},{"key":"e_1_3_2_1096_2","unstructured":". 2018. Tavalisse (fostamatinib disodium hexahydrate). Reference ID 4249943. Prescribing information. Food and Drug Administration Silver Spring MD. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/209299lbl.pdf. Accessed August 2019."},{"key":"e_1_3_2_1097_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu273"},{"key":"e_1_3_2_1098_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23992"},{"key":"e_1_3_2_1099_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.38851"},{"key":"e_1_3_2_1100_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140238"},{"key":"e_1_3_2_1101_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25125"},{"key":"e_1_3_2_1102_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205361"},{"key":"e_1_3_2_1103_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70344-3"},{"key":"e_1_3_2_1104_2","doi-asserted-by":"publisher","DOI":"10.4155\/cli.11.92"},{"key":"e_1_3_2_1105_2","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181c4dedb"},{"key":"e_1_3_2_1106_2","unstructured":"European Medicines Agency. 2018. Xalkori INN\u2014crizotinib. Product information. European Medicines Agency Amsterdam The Netherlands. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002489\/WC500134759.pdf. Accessed August 2019."},{"key":"e_1_3_2_1107_2","unstructured":". 2018. Xalkori (crizotinib). Prescribing information. Reference ID 4216933. Food and Drug Administration Silver Spring MD. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/202570s023lbl.pdf. Accessed August 2019."},{"key":"e_1_3_2_1108_2","unstructured":"Therapeutic Goods Administration. 2018. Australian product information\u2014Xalkori (crizotinib). Therapeutic Goods Administration Woden Australia. https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2013-PI-02261-1. Accessed August 2019."},{"key":"e_1_3_2_1109_2","unstructured":"European Medicines Agency. 2018. Zykadia INN\u2014ceritinib. Product information. European Medicines Agency Amsterdam The Netherlands. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003819\/WC500187504.pdf. Accessed August 2019."},{"key":"e_1_3_2_1110_2","unstructured":". 2018. Zykadia (ceritinib). Prescribing information. Reference ID 3497722. Food and Drug Administration Silver Spring MD. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/205755s000lbl.pdf. Accessed August 2019."},{"key":"e_1_3_2_1111_2","unstructured":"Therapeutic Goods Administration. 2018. Australian product information\u2014Zykadia (ceritinib). Therapeutic Goods Administration Woden Australia. https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2016-PI-01610-1. Accessed August 2019."},{"key":"e_1_3_2_1112_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704795"},{"key":"e_1_3_2_1113_2","unstructured":"European Medicines Agency. 2018. Alecensa INN\u2014alectinib. Product information. European Medicines Agency Amsterdam The Netherlands. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004164\/WC500225707.pdf. Accessed August 2019."},{"key":"e_1_3_2_1114_2","unstructured":". 2017. Alecensa (alectinib). Prescribing information. Reference ID 4177381. Food and Drug Administration Silver Spring MD. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208434s003lbl.pdf. Accessed August 2019."},{"key":"e_1_3_2_1115_2","unstructured":"Therapeutic Goods Administration. 2018. Australian product information\u2014Alecensa (alectinib). Therapeutic Goods Administration Woden Australia. https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2017-PI-01495-1&d=201809061016933. Accessed August 2019."},{"key":"e_1_3_2_1116_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214886"},{"key":"e_1_3_2_1117_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30392-8"},{"key":"e_1_3_2_1118_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408440"},{"key":"e_1_3_2_1119_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00614-2"},{"key":"e_1_3_2_1120_2","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyu183"},{"key":"e_1_3_2_1121_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-015-0284-9"},{"key":"e_1_3_2_1122_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-014-0195-1"},{"key":"e_1_3_2_1123_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406766"},{"key":"e_1_3_2_1124_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30123-X"},{"key":"e_1_3_2_1125_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30339-X"},{"key":"e_1_3_2_1126_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30565-2"},{"key":"e_1_3_2_1127_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.02.022"},{"key":"e_1_3_2_1128_2","doi-asserted-by":"publisher","DOI":"10.7150\/thno\/v01p0154"},{"key":"e_1_3_2_1129_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0902-918"},{"key":"e_1_3_2_1130_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2004.02.021"},{"key":"e_1_3_2_1131_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(02)00971-6"},{"key":"e_1_3_2_1132_2","first-page":"107","article-title":"Integrins: a review of their structure and mechanisms of ligand binding","volume":"47","author":"Tuckwell DS","year":"1993","unstructured":"Tuckwell DS, Weston SA, Humphries MJ. 1993. Integrins: a review of their structure and mechanisms of ligand binding. Symp Soc Exp Biol 47:107\u2013136.","journal-title":"Symp Soc Exp Biol"},{"key":"e_1_3_2_1133_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007621.pub2"},{"key":"e_1_3_2_1134_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000320512.21919.d2"},{"key":"e_1_3_2_1135_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215734"},{"key":"e_1_3_2_1136_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215739"},{"key":"e_1_3_2_1137_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0094-8"},{"key":"e_1_3_2_1138_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.11.013"},{"key":"e_1_3_2_1139_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14631"},{"key":"e_1_3_2_1140_2","doi-asserted-by":"publisher","DOI":"10.2165\/0128071-200910010-00009"},{"key":"e_1_3_2_1141_2","doi-asserted-by":"publisher","DOI":"10.3310\/hta10460"},{"key":"e_1_3_2_1142_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.05.033"},{"key":"e_1_3_2_1143_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2011.524925"},{"key":"e_1_3_2_1144_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1990.03450010083036"},{"key":"e_1_3_2_1145_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051847"},{"key":"e_1_3_2_1146_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051782"},{"key":"e_1_3_2_1147_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051586"},{"key":"e_1_3_2_1148_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30282-X"},{"key":"e_1_3_2_1149_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003739"},{"key":"e_1_3_2_1150_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12304"},{"key":"e_1_3_2_1151_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30040-1"},{"key":"e_1_3_2_1152_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2010.164"},{"key":"e_1_3_2_1153_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2017.07.018"},{"key":"e_1_3_2_1154_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01188"},{"key":"e_1_3_2_1155_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000423208.11698.16"},{"key":"e_1_3_2_1156_2","unstructured":"Foley J Carillo-Infante C Wenten M Lavallee N Smith J Evans K Haddock B Steiner D Ho P-R Lee L Vermersch P Hutchinson M Pozzilli C Bloomgren G. 2016. Long-term safety of natalizumab treatment in multiple sclerosis (MS) in clinical practice: results from the tysabri global observational program in safety (TYGRIS) abstr P1229. ECTRIMS 2016 Congr London United Kingdom 14 to 17 September 2016."},{"key":"e_1_3_2_1157_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13215"},{"key":"e_1_3_2_1158_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri2686"},{"key":"e_1_3_2_1159_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k2179"},{"key":"e_1_3_2_1160_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"e_1_3_2_1161_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0367"},{"key":"e_1_3_2_1162_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02140"},{"key":"e_1_3_2_1163_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-625343"},{"key":"e_1_3_2_1164_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18004"},{"key":"e_1_3_2_1165_2","doi-asserted-by":"publisher","DOI":"10.1183\/1393003.congress-2017.OA1478"},{"key":"e_1_3_2_1166_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw539"},{"key":"e_1_3_2_1167_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00108"},{"key":"e_1_3_2_1168_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2017.04.177"},{"key":"e_1_3_2_1169_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy210.1384"},{"key":"e_1_3_2_1170_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12838"},{"key":"e_1_3_2_1171_2","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000194"},{"key":"e_1_3_2_1172_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158262"},{"key":"e_1_3_2_1173_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01995"},{"key":"e_1_3_2_1174_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.07.006"},{"key":"e_1_3_2_1175_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1250LE"},{"key":"e_1_3_2_1176_2","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S178246"},{"key":"e_1_3_2_1177_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.03.012"},{"key":"e_1_3_2_1178_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.12.003"},{"key":"e_1_3_2_1179_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat2702"},{"key":"e_1_3_2_1180_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00157-2017"},{"key":"e_1_3_2_1181_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw838"},{"key":"e_1_3_2_1182_2","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000528"},{"key":"e_1_3_2_1183_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0379-x"},{"key":"e_1_3_2_1184_2","doi-asserted-by":"publisher","DOI":"10.1111\/pim.12596"},{"key":"e_1_3_2_1185_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1700840"},{"key":"e_1_3_2_1186_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18112413"},{"key":"e_1_3_2_1187_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000003685"},{"key":"e_1_3_2_1188_2","doi-asserted-by":"publisher","DOI":"10.1186\/cc14003"},{"key":"e_1_3_2_1189_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01147"},{"key":"e_1_3_2_1190_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6918"},{"key":"e_1_3_2_1191_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan3706"},{"key":"e_1_3_2_1192_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy103"},{"key":"e_1_3_2_1193_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24751"},{"key":"e_1_3_2_1194_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.01.017"},{"key":"e_1_3_2_1195_2","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1568812"},{"key":"e_1_3_2_1196_2","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1507670"},{"key":"e_1_3_2_1197_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(89)90350-3"},{"key":"e_1_3_2_1198_2","doi-asserted-by":"publisher","DOI":"10.2174\/092986706777441959"},{"key":"e_1_3_2_1199_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-198709000-00021"},{"key":"e_1_3_2_1200_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-198710000-00004"},{"key":"e_1_3_2_1201_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000081587.96151.77"},{"key":"e_1_3_2_1202_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-198409000-00001"},{"key":"e_1_3_2_1203_2","doi-asserted-by":"publisher","DOI":"10.2165\/11208300-000000000-00000"},{"key":"e_1_3_2_1204_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003573"},{"key":"e_1_3_2_1205_2","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/9874261"},{"key":"e_1_3_2_1206_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2017.02.007"},{"key":"e_1_3_2_1207_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2013.02.062"},{"key":"e_1_3_2_1208_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14001"},{"key":"e_1_3_2_1209_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2015.06.029"},{"key":"e_1_3_2_1210_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2015.08.004"},{"key":"e_1_3_2_1211_2","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13129"},{"key":"e_1_3_2_1212_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-876805"},{"key":"e_1_3_2_1213_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-876136"},{"key":"e_1_3_2_1214_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4419-5635-4_10"},{"key":"e_1_3_2_1215_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-2222"},{"key":"e_1_3_2_1216_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3182503849"},{"key":"e_1_3_2_1217_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.170508"},{"key":"e_1_3_2_1218_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.03.087"},{"key":"e_1_3_2_1219_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-017-1090-4"},{"key":"e_1_3_2_1220_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2018.10.015"},{"key":"e_1_3_2_1221_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy958"},{"key":"e_1_3_2_1222_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15790"},{"key":"e_1_3_2_1223_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6627e1"},{"key":"e_1_3_2_1224_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-2452"},{"key":"e_1_3_2_1225_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.07.011"},{"key":"e_1_3_2_1226_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-011-1929-3"},{"key":"e_1_3_2_1227_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-2924-y"},{"key":"e_1_3_2_1228_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24632"},{"key":"e_1_3_2_1229_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbre.2015.08.004"},{"key":"e_1_3_2_1230_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i43.16014"},{"key":"e_1_3_2_1231_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq368"},{"key":"e_1_3_2_1232_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201244"},{"key":"e_1_3_2_1233_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbre.2017.05.005"},{"key":"e_1_3_2_1234_2","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12659"},{"key":"e_1_3_2_1235_2","doi-asserted-by":"publisher","DOI":"10.1086\/430000"},{"key":"e_1_3_2_1236_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3238"},{"key":"e_1_3_2_1237_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12930"},{"key":"e_1_3_2_1238_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw172.1884"},{"key":"e_1_3_2_1239_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.3675.3675"},{"key":"e_1_3_2_1240_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10564"},{"key":"e_1_3_2_1241_2","first-page":"496","article-title":"Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity","volume":"91","author":"Brusamolino E","year":"2006","unstructured":"Brusamolino E, Rusconi C, Montalbetti L, Gargantini L, Uziel L, Pinotti G, Fava S, Rigacci L, Pagnucco G, Pascutto C, Morra E, Lazzarino M. 2006. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica 91:496\u2013502.","journal-title":"Haematologica"},{"key":"e_1_3_2_1242_2","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2072-1439.2013.08.35"},{"key":"e_1_3_2_1243_2","doi-asserted-by":"publisher","DOI":"10.2217\/ijr.12.31"},{"key":"e_1_3_2_1244_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201956"},{"key":"e_1_3_2_1245_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.103"},{"key":"e_1_3_2_1246_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.34359"},{"key":"e_1_3_2_1247_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.27541"},{"key":"e_1_3_2_1248_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar3337"},{"key":"e_1_3_2_1249_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210457"},{"key":"e_1_3_2_1250_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0880-2"},{"key":"e_1_3_2_1251_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-018-0097-3"},{"key":"e_1_3_2_1252_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.03.023"},{"key":"e_1_3_2_1253_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209131"},{"key":"e_1_3_2_1254_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207319"},{"key":"e_1_3_2_1255_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu172"},{"key":"e_1_3_2_1256_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507247"},{"key":"e_1_3_2_1257_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210094"},{"key":"e_1_3_2_1258_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608345"},{"key":"e_1_3_2_1259_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.161161"},{"key":"e_1_3_2_1260_2","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2017.1307899"},{"key":"e_1_3_2_1261_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0417-z"},{"key":"e_1_3_2_1262_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409002"},{"key":"e_1_3_2_1263_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.148"}],"container-title":["Clinical Microbiology Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CMR.00035-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CMR.00035-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T03:57:57Z","timestamp":1723003077000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CMR.00035-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,17]]},"references-count":1262,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6,17]]}},"alternative-id":["10.1128\/CMR.00035-19"],"URL":"https:\/\/doi.org\/10.1128\/cmr.00035-19","relation":{},"ISSN":["0893-8512","1098-6618"],"issn-type":[{"value":"0893-8512","type":"print"},{"value":"1098-6618","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,17]]},"assertion":[{"value":"2020-06-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00035-19"}}